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University of Nebraska, 2019

Advisor: Surinder K. Batra, Ph.D.
Pancreatic cancer (PC) is one of the most lethal malignancies, and since 53% of
patients are diagnosed with the advanced metastatic stage of the disease,
handling/targeting this aggressive metastatic cancer becomes a challenge. The present
therapy for PC includes gemcitabine, Abraxane, erlotinib, FOLFIRINOX, and their
combinations. All of these therapies along with surgical interventions have so far
increased the average five-year survival for PC patients to 7.2%. One of the chief
contributors for this dismal prognosis of pancreatic cancer is cancer stem cell (CSC)
population, which are responsible for the aggressive and refractory nature of the
disease. CSCs are a small subpopulation in the tumor, which are held accountable for
early metastasis, drug resistance and disease relapse in different cancers including PC
[1-3]. Cancer stem cells (CSC) are primary culprits for aggressive metastatic nature of
pancreatic cancer, and present therapies fail to target CSC. EGFR family of proteins is
vital for CSC self-renewal and maintenance and necessary for PC initiation and
progression. In this thesis, we aim to develop a targeted therapy for pancreatic cancer
by targeting cancer stem cell population thereby decreasing the metastasis.
In the first part of this thesis, we utilize tissue murine and human origin to develop threedimensional organoids to be able to evaluate therapy response in them. We show that
we successfully generate organoids for mouse pancreatic cancer, normal pancreas,
human PDAC samples, and mouse prostate and lungs. We engage PDAC organoids for
further studies and show retention and expansion of different subsets of cancer stem cell
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population in these organoids. We also standardize a method to evaluate growth and
inhibition in established organoids.
In the second part of this thesis, we evaluated a targeted therapy using panEGFR inhibitor, Afatinib, aimed at inhibiting Pancreatic CSC and hence abrogate tumor
and metastasis. We begin by demonstrating the presence of higher CSC in patients
treated with chemotherapy compared to patients with no history of chemotherapy
highlighting the presence and role of CSC in PDAC. We then demonstrate the efficacy of
treatment with Afatinib alone and in combination with gemcitabine in organoids derived
from human PDAC patients. We also show inhibition of primary tumor and metastatic
incidence in an orthotopic mouse model of pancreatic cancer by combination therapy of
Afatinib and gemcitabine. We also look at changes in the CSC population, KPC
organoids and primary tumors in an orthotopic mouse model and find a significant
decrease. Upon evaluation of effects of Afatinib on CSC population and KC, KPC
organoids we reveal that Afatinib inhibits CSC stemness by downregulating CSC and
self-renewal markers. Finally, we provide a mechanism of action for Afatinib and its
validation by knockdown studies. Our findings indicate that Afatinib inhibits pancreatic
CSC via EGFR/ ERK/ FOXA2/ SOX9 axis and a combination of Afatinib and gemcitabine
is an efficient therapy for metastatic pancreatic cancer.

.
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CHAPTER 1: REVIEW OF THE LITERATURE
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1.1 Introduction
Pancreatic cancer (PC) accounts for 3% of cancer instances in the United States (US)
but claims 7% of all cancer-related deaths. The past 30 years of constant efforts have
managed to increase the five-year median survival rates from 3% to 9% [4]. Such dismal
patient

survival

warrants

better

therapeutic

interventions.

Pancreatic

ductal

adenocarcinoma (PDAC) is the most common form/manifestation of PC. Late diagnosis
of PDAC, due to the internal location of the organ and lack of distinct symptoms, leaves
PC patients with very few therapeutic options. Additionally, PC poses major recalcitrance
to therapy due to extensive stroma which prevents drugs from accessing tumor cells and
the presence of therapy-resistant cells or cancer stem cells (CSCs). Furthermore, PC is
now being proposed as a systemic disease starting from its conception and hence early
metastasis warrants development of systemic therapies [5].
Projections indicate that PC will be the second most common cause of death in
the USA by 2030 with only non-small cell lung carcinoma (NSCLC) ahead of it [6]. PC
patients when diagnosed have limited options for therapy. Over 50% of patients when
diagnosed with PC, present a late stage disease with local and distant metastasis [4].
Most of these patients are not suitable for surgical resection, surgery being the only
curative treatment available offers a survival of 15-20% [7]. However, most patients are
not eligible for surgery. On diagnosis, cancer is staged from one to four on the basis of
imaging and biopsies. Stage one and two are often surgically resectable but stage three
is locally advanced and surgically unresectable and stage four is distant metastatic
cancer.
We saved around 11,000 lives in 2018 out of over 55,000 patients diagnosed
with PC. This is where we stand on the road to therapy for PC. This figure although
discouraging shows us how much more we can do. There is a lot unknown about the
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disease. In this review, we discuss where we stand in the fight against PC, some
available therapies and some options that may turn this fight in our favor. We also
discuss some issues that need addressing for a better analysis of clinical trial results and
future research avenues.

1.2 Resectable Pancreatic Cancer

1.2.1 Adjuvant Therapy
Surgery is currently the only potentially curative procedure available for PDAC. However
more than 90% of patients that undergo surgery show relapse and would die if not
supplemented with additional therapy [7]. This is precisely the reason that adjuvant
treatment has been the subject for several clinical trials in the last decade. The patients
eligible for adjuvant therapy are advised chemotherapy, radiotherapy or a combination
(Chemoradiotherapy; CRT) of both. Since the Gastrointestinal Tumor Study Group
(GITSG) trial in 1985 many trials have compared different adjuvant therapy regimens
and if there is a need for adjuvant therapy [8]. GITSG was a randomized phase 3 trial
that enrolled 43 patients and compared the adjuvant therapy of 5 fluorouracil (5FU)
chemo with radiotherapy followed by two years of 5FU alone to observation only. The
trial was terminated due to poor accrual of patients and increasingly large survival
difference between study arms, but a significant difference in average survival of control
arm vs. treatment arm (11 months vs. 20 months) could be observed. Although the study
only recruited patients with negative resection margins thereby selecting people already
prognostically favored, its results did impress upon the survival benefit of adjuvant
therapy over no therapy after surgical resection of the tumor. Many studies after that
have looked at the benefit of therapy after surgical intervention. Two options often
recommended to patients are CRT and chemotherapy alone. An European organization
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for research and treatment of cancer (EORTC) multicenter phase 3 randomized trial
enrolled 218 patients and compared the benefits of adjuvant CRT versus observation
only and found that CRT offers a survival advantage which was not statistically
significant (overall survival of 17.1 months in treatment vs. 12.6 months in observationonly arm); [9]. Another study by European Study Group for Pancreatic Cancer (ESPAC),
published a multicentral randomized trial (ESPAC1) in 2004 which recruited 289 patients
and tried to weigh chemotherapy, CRT and observation only against each other [10].
They compared the 5-year survival rates and found that 5FU-based-CRT offers a
survival disadvantage over observation alone (10% versus 20% 5-year survival rates
P=0.05). But 5-FU-chemotherapy after R0 or R1 resection showed a survival advantage
by increasing 5-year survival to 21% when compared to no chemotherapy which was 8%
(P=0.009). This survival benefit was very encouraging since 18 percent of the patients
had positive resection margins, which was an exclusion criterion in the GITSG clinical
trial [8],[10]. The CRT and hence its negative results in ESPAC1 trial were criticized by
the radio-oncologists; on the contrary, similar survival results for CRT were observed in
RTOG97-04 trial [11]. RTOG97-04 trial compared CRT with 5FU to CRT with 5FU
followed by Gemcitabine and found no survival benefits.
Although ESPAC1 study proved the benefit of 5-FU chemotherapy as adjuvant
therapy, out of 289 patients enrolled 237 died by the end of the study. This still means
only 12% of enrolled patients survived. Cumulative results of this study put a serious
question on the use of CRT as adjuvant therapy, by highlighting the detrimental effects
of chemoradiation. Radiation therapy administration delays chemo administration and
may also generate a more resistant tumor population if we consider the recent studies
published, which claim radiation therapy enriches the cancers stem cell population [12,
13]. These may be the reason behind the overall decrease in 5-year survival with CRT.
A small sample size of GITSG study along with results published from EORTC study and
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ESPAC1 trial overwhelmed the GITSG study results and favored chemotherapy as the
more effective adjuvant therapy. A meta-analysis of randomized adjuvant therapy trials
done by Stocken et al. in 2005 compared five trials including ESPAC and concluded that
adjuvant therapy reduces the risk of death by 25% which was statistically significant[14].
There was a median survival of 19 months with chemotherapy and 13.5 months without
it. Whereas, chemoradiation showed no significant difference in the risk of death with
median survivals of 15.8 months with chemoradiation and 15.2 months without.
Subgroup analysis revealed chemoradiation was more effective (p=0.04) when
compared to chemotherapy (p=0.007) in patients with a positive resection margin [14].
Over time, multiple studies have compared various adjuvant chemotherapy regimens out
of which some notable drugs are gemcitabine and 5FU, a combination of both and
FOLFIRINOX (folinic acid, fluorouracil, irinotecan hydrochloride and oxaliplatin). Since its
arrival in the scenario of PC therapy in 1996, gemcitabine has taken center stage as a
standard of care for treatment of this disease. CONKO-001, a multicentral phase 3
randomized clinical trial compared median disease-free survival, 5-year overall survival
and 10-year survival of 368 patients divided into two groups of gemcitabine adjuvant
therapy and observation alone [15]. The results depicted that gemcitabine adjuvant
therapy led to a median disease-free survival of 13.4 months compared to 6.7 months
with observation only. Gemcitabine group also had increased overall 5-year (20.7%) and
10-year (12.2%) survivals compared to control groups of observation only 5-year
(10.4%) and 10-year (7.7%) survival rates [15, 16]. Enduringly, ESPAC 3 compared 5FU
with folinic acid versus gemcitabine and found no statistical difference in the survival
advantage offered by the two drug regimens [17]. The median survival of 5FU + folinic
acid was 23.0 months compared 23.6 months with gemcitabine. Median progressionfree survival was also 14.1 and 14.3 months respectively. Although gemcitabine alone
did not have a significant survival advantage over 5FU+folinic acid, its toxicity profile was
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significantly better than later. A retrospective analysis of ESPAC 3 trial suggested a role
of ENT1 (equilibrative nucleoside transporter 1, a key mediator for gemcitabine cellular
uptake) in stratifying patients for adjuvant administration of gemcitabine [17, 18]. Another
prospective study analyzed the prognostic influence of gemcitabine-related genes
(hENT1, ribonucleotide reductase subunits (RRM1, RRM2), and deoxycytidine kinase
(dCK) ) in 100 patients undergone gemcitabine adjuvant therapy and identified low
expression of hENT1 and dCK, and high/moderate levels of RRM1 as negative
prognostic factors [19]. These studies suggest stratification of patients before adjuvant
therapy administration although further prospective validation is required. Other
components of major drug metabolic pathways could be used to refine therapeutic
approaches further and generate more personalized treatment regimens. Patient
prognosis was also influenced by the ability of the patient to complete all six cycles of
chemotherapy [20]. Considering CONKO-001 trial results that established a 6-month
course of adjuvant chemotherapy (gemcitabine) as the standard of care for resected PC
patients and the positive results of the PA.3 phase III trial [21] demonstrating a survival
benefit from the addition of erlotinib to gemcitabine (although in metastatic disease)
CONKO-005 trial was designed [22]. The trial revealed no difference in median diseasefree survival or median overall survival of gemcitabine and erlotinib combination over
gemcitabine alone. Although a trend toward better long-term survival in favor of
gemcitabine and erlotinib group was observed (estimated survival after 1, 2, and five
years for combination group was 77%, 53%, and 25% v 79%, 54%, and 20% for
gemcitabine alone group, respectively). A randomized phase III clinical trial conducted
on Japanese population revealed adjuvant therapy of S-1 (combination of tegafurchemotherapeutic prodrug of 5FU, and chemotherapeutic adjuncts gimeracil (Stabilises
5FU) and oteracil potassium(reduces 5FU activity)) provided a 5-year survival of 44.1%
compared to gemcitabine which allowed a 5-year survival of 24.4% [23]. Hence, the
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study proposed S-1 as a standard of care for PDAC although the results of this study
have not been confirmed in non-Asian populations. A recent trial ESPAC-4 compared
gemcitabine monotherapy with gemcitabine plus capecitabine combination therapy in
patients with R0 (42% patients) or R1 (60% patients) resected PC. Median overall
survival was 28 months for patients in the gemcitabine plus capecitabine group
compared with 25·5 months in the gemcitabine group [24, 25]. Consequently, in 2017
the American Society of Clinical Oncology (ASCO) clinical practice guidelines were
updated for potentially curable PC. Updated guidelines direct patients with resected PC
and no prior preoperative therapy to be offered 6 months of adjuvant chemotherapy in
the absence of medical contraindications. In patients with no concerns for toxicity or
tolerance, the doublet regimen of gemcitabine and capecitabine should be preferred.
Alternatively, monotherapy with gemcitabine or 5-FU plus FA can be offered as an
adjuvant treatment initiated within 8 weeks of surgical resection, assuming complete
recovery [26]. Another important clinical trial named APACT compares doublet therapy
of nab-paclitaxel plus gemcitabine with gemcitabine monotherapy, and its results are still
pending [27]. In 2018 results of PRODIGE 24/CCTG PA.6 trial were released which
showed a large increment in treatment benefit over gemcitabine [28]. PRODIGE 24 was
a randomized phase III trial including 493 patients with surgically removed PC. The trial
compared mFOLFIRINOX (modified FOLFIRINOX containing oxaliplatin, leucovorin,
irinotecan, and fluorouracil) with gemcitabine adjuvant therapies given 3 to 12 weeks
after surgery for 6 months. The median disease-free survival and median overall survival
observed in the mFOLFIRINOX group (21.6 and 54.4 months) was higher than in the
gemcitabine group (12.8 and 35.0 months). At a median follow up patients in
mFOLFIRINOX lived a median of 20 months longer. Patients in the mFOLFIRINOX
group also exhibited delayed metastasis (median = 30.4 months vs. 17.0 months with
gemcitabine) and were cancer-free 9 months longer than those who received
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gemcitabine. Overall, mFOLFIRINOX led to more severe symptoms for patients but were
mostly manageable as the authors of the study report[28]. The symptoms described for
mFOLFIRINOX included diarrhea, nausea, vomiting, and fatigue. The side effects
mentioned for gemcitabine included swelling, headache, flu-like symptoms, and low
white blood cell counts. Both treatments were reported to cause low levels of white blood
cells and fever [28].

1.2.2 Neoadjuvant Therapy
Immediate surgery followed by chemotherapy is the current standard of care for PC
patients with a resectable disease, but an emerging strategy for resectable, borderline
resectable or locally advanced unresectable cancer is neoadjuvant therapy [25]. In this
scheme

of

treatment

patients

are

given

radiotherapy,

chemotherapy

or

chemoradiotherapy followed by surgically removing the tumor, also called preoperative
therapy [25, 29]. The first randomized clinical trial results for neoadjuvant therapy came
in 2015 [25]. Which compared neoadjuvant chemoradiation with gemcitabine/cisplatin
and surgery to surgery alone [30]. The trials concluded that the preoperative treatment
was safe concerning toxicity and mortality, but the results were not statistically
significant. The trial had to be terminated due to slow accrual before it could be
completed. Apart from this study, there had been several meta-analyses and few
prospective and nonrandomized trials

evaluating

the benefits

of neoadjuvant

chemoradiotherapy (mostly gemcitabine-based) but no notable randomized trials [31].
The first randomized, phase III trial (PREOPANC-1) that found that patients who
received chemoradiotherapy before pancreatic cancer surgery (preoperative) had better
disease-free survival than those who started their treatment with surgical tumor
resection, which is the current standard of care, were released in 2018 [29]. The trial
enrolled 246 patients eligible for surgical resectable pancreatic cancer who were
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randomly assigned to two groups. The first group received immediate surgery and the
second group received chemoradiotherapy for ten weeks followed by surgery. Both the
treatment regimens were followed by chemotherapy after surgery, with the total amount
of chemotherapy given being equal in both groups. Chemotherapy was delivered in two
parts in the chemoradiotherapy group which received part of the before surgery and the
rest after [29]. The median overall survival and time until pancreatic cancer recurrence
was higher for patients receiving preoperative chemoradiotherapy (17.1 and 9.9months)
when compared with the ones who underwent immediate surgery (13.7 and 7.9 months).
Two years survival rate was also higher with preoperative treatment than with immediate
surgery (42% vs. 30%). 72% of patients underwent resection in the immediate-surgery
group and 62% in the chemoradiotherapy group [29]. A higher proportion of preoperative
treatment group patients saw successful microscopic surgical resection when compared
to the immediate surgery group (63% vs. 31%). Among patients with R0 margins, the
difference in median survival was greater, 42.1 months with preoperative treatment
versus

16.8 months

with immediate surgery. FOLFIRINOX chemotherapy or

FOLFIRINOX combined with stereotactic body radiation therapy appear promising from
other studies and should be tested against preoperative gemcitabine and radiation in a
randomized clinical trial [32].
Another multicenter, randomized controlled phase III trial called NorPACT- 1
investigates benefits of neoadjuvant chemotherapy based on FOLFIRINOX over surgery
with both groups receiving adjuvant chemotherapy with gemcitabine and capecitabine in
90

patients

[33].

The

trial

was

organized

by

the

Norwegian

Gastrointestinal Cancer Group for Hepato-Pancreato-Biliary cancer for resectable
cancer of the pancreatic head to decrease early mortality (within one year) in resected
patients. Another notable multicenter randomized phase III trial designed to explore the
efficacy of neoadjuvant chemotherapy is NEOPAC trial [33]. In patients with resectable
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pancreatic adenocarcinoma in the head of the pancreas were randomized to surgery
followed by adjuvant gemcitabine for six months or neoadjuvant gemcitabine and
oxaliplatin followed by surgery and the same adjuvant treatment. Neoadjuvant
chemotherapy would be given four times every two weeks [33].
Neoadjuvant chemoradiation is also being evaluated for providing substantial local
control of borderline resectable pancreatic cancer and prolong patient survival. An openlabel, multicentre, prospective phase II trial that was designed to assess S-1
chemotherapy with radiotherapy as neoadjuvant treatment [34]. Participants would
receive S-1 and concurrent radiotherapy, with surgery after 3-8 weeks which will last 36month period with a minimum 24-month follow-up [34].

1.3 Nonresectable disease

1.3.1 Locally advanced unresectable pancreatic cancer (LAPC)
More than half of the patients that present with pancreatic cancer are diagnosed at the
LAPC stage and have a discouraging survival rate of less than 5% [25]. These groups of
patients depict local invasion of adjacent structures, generally vascular and are
challenging to treat. Unlike resectable PC, LAPC patients rarely undergo resection with a
curative intent instead of local control, symptom management and quality of life are the
primary goals of the therapy [25].
Initial systemic (induction) chemotherapy with combination regimens is usually
recommended for most patients who can tolerate aggressive therapy. There is
conflicting evidence for chemoradiotherapy versus gemcitabine chemotherapy alone
[25]. ECOG (Eastern Cooperative Oncology Group) 42201 trial results in favor
chemoradiotherapy whereas 2000‑ 01 Fédération Francophone de Cancérologie
Digestive (FFCD)/Sociéte Française de Radiothérapie Oncologique (SFRO) trial favors
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gemcitabine chemotherapy alone [35, 36]. No standard therapy is proven to be clinically
superior to others, and hence an informed decision has to be made by the physicians
considering risks and benefits for the patients. Therapies recommended for metastatic
patients are often referred to due to lack of evidence for LAPC.
Since 1997 till 2011 gemcitabine was considered standard of care for patients with
unresectable pancreatic cancer. A definitive clinical trial assessing Gemcitabine versus 5
FU as first-line treatments for patients with locally advanced pancreatic cancer was
conducted [37]. Results from this trial established that gemcitabine improves diseaserelated symptoms and survival in patients with pancreas cancer (5.6 vs. 4.4 months)
[37]. Although the overall survival increment was small, the 12 months survival rate was
improved significantly (18% for gemcitabine vs. 2% for 5-FU patients). Many trails since
have worked on improving the overall survival and quality of life for patients with
advanced pancreatic cancer by adding one or more drugs to gemcitabine and exploring
different schedules (fix dose rate) of its administration. None of the trials resulted in
clinically appreciable improvement in patient survival over gemcitabine till 2011,
PRODIGE4/ACCORD11 trial which revealed FOLFIRINOX, a combination of 4 drugs
(irinotecan, oxaliplatin, folinic acid, and 5-fluorouracil) showed a moderate improvement
in overall survival of patients [28]. Local therapies for the management of tumors are
recommended if the patients do not show a metastatic disease after induction
chemotherapy. Several Local, regional therapies have been tested for LAPC
management including irreversible electroporation (IRE), radiofrequency ablation (RFA),
stereotactic body radiation (SBRT), high- intensity focused ultrasound (HIFU) [38]. RFA
and SBRT are the best-studied modalities, and SBRT is the only treatment that has
resulted in the quality of life improvements in patients with LAPC. SBRT has been
studied with varying guiding techniques and radiation doses applied, and morbidity has
been reported in up to 25% of patients [38]. SBRT minimizes the disruption in
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chemotherapy since higher doses of radiation is given in shorter durations in contrast to
radiotherapy. ASCO included SBRT in their recommendations for LAPC in 2016 [39].
Chemoradiotherapy or SBRT may be offered as an alternative to continuing
chemotherapy alone for any patient with LAPC. CRT or SBRT may also be offered to
patients who show local disease progression or toxicities after induction chemotherapy
[38]. A short course of palliative radiotherapy (5 to 10 treatments) may be offered to
patients with LAPC who have severe GI symptoms. Prolonged survival, better
symptomatic management, and tumor regression as a result of local ablative therapies,
has been reported in several studies [38]. However, utilization of local treatments should
undergo further evaluation since approximately 30% to 50% of patients presenting with
LAPC have evidence of metastatic disease within three months. Owing to the lack of
RCTs conclusive data supporting local ablative therapies for LAPC is sparse [38].

1.3.2 Advanced metastatic pancreatic cancer
Gemcitabine became the standard of care and choice for first-line therapy against
advanced metastatic pancreatic cancer since the Burris et al. trial in 1997 [37]. Other
Phase III trials since then evaluating single-agent gemcitabine monotherapy for
advanced pancreatic cancer yielded a median survival of 5.0 to 7.2 months for patients
[40]. In 2006, a Randomized phase III trial compared gemcitabine plus cisplatin with
gemcitabine alone in patients with advanced PC. The trial included 195 patients and the
doublet therapy arm showed a prolonged progression-free survival compared to
gemcitabine monotherapy (5.3 months v 3.1 months). Median overall survival was also
enhanced in patients treated with a combination of gemcitabine and cisplatin as
compared with the Gemcitabine (7.5 v 6.0 months). However, it was not statistically
significant. The results from this trial favored the combination of gemcitabine with
cisplatin over gemcitabine monotherapy [40]. Another trial from the Swiss Group for
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Clinical Cancer Research and the Central European Cooperative Oncology Group
compared Gemcitabine plus capecitabine combination therapy with gemcitabine
monotherapy in advanced pancreatic cancer in a randomized, multicenter, phase III trial
[41]. Median overall survival was improved although not significantly with the addition of
capecitabine by an average of 1.2 months (8.4 months in Gemcitabine and capecitabine
arm vs. 7.2 months in Gemcitabine arm). Further analysis of the trial reviled that the
combination therapy was significantly beneficial for patients with good performance
score (KPS of 90 to 100) with median overall survival being 10.1 months for combination
group versus 7.4 months for Gemcitabine group. Additionally, a meta-analysis of
randomized clinical trials indicated a significant survival benefit to patients when
Gemcitabine base therapies combined with either platinum analogs or fluoropyrimidines.
Their subgroup analysis that included 38% of all patients included in the meta-analysis,
Gemcitabine-based combination therapies were beneficial for patients with a good
performance score but not for patients with a poor performance score [42]. Around the
same time phase II studies showing survival advantage and benefits of single-agent
Irinotecan, and oxaliplatin combination with fluorouracil came out [43, 44]. Considering
synergistic observed between Oxaliplatin and irinotecan in vivo, an open-label phase I
study assessed the triple combination of oxaliplatin plus irinotecan plus leucovorin/5fluorouracil in patients with advanced solid tumors and saw encouraging results. This
prompted a phase II and later Phase III trial comparing a combination chemotherapy
regimen of FOLFIRINOX (oxaliplatin, irinotecan, fluorouracil, and leucovorin) with
gemcitabine as first-line therapy in patients with metastatic pancreatic cancer (PRODIGE
4/ACCORD 11) [28]. The median overall survival and progression-free survival were
both enhanced FOLFIRINOX group versus gemcitabine group(11.1 vs. 6.8 months and
6.4 vs. 3.3 months, respectively) [28]. The trial reported FOLFIRINOX to be associated
with a survival advantage but increased toxicity. Another phase III MPACT trial
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compared nab-paclitaxel and gemcitabine combination therapy versus gemcitabine
alone in patients with metastatic pancreatic cancer [28]. The study demonstrated a
significant survival advantage of nab-paclitaxel and gemcitabine (8.5 vs. 6.7 months).
Progression-free survival was also improved with the combination therapy over
gemcitabine monotherapy (5.5 vs. 3.7 months). After the results of MPACT and
PRODIGE trials, ASCO guidelines were updated to include the proposed therapies.
Gemcitabine plus NAB-paclitaxel was recommended for patients with Eastern
Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1, relatively
favorable comorbidity profile, and tolerability for relatively aggressive medical therapy
[28]. Whereas, FOLFIRINOX (leucovorin, fluorouracil, irinotecan, and oxaliplatin) was
recommended for patients who have an ECOG PS 0 or 1, favorable comorbidity profile,
and can tolerate aggressive medical therapy, with access to chemotherapy port and
infusion pump management services. On the other hand, patients with metastatic
pancreatic

cancer

ECOG performance

status, two are referred gemcitabine

monotherapy according to the ASCO Clinical Practice Guidelines updated in 2018 [45].

Another approach is to capitalize on the hypoxic environment in pancreatic
cancer. TH-302 is a prodrug of cytotoxin Bromo-isophosphoramide mustard (Br-IPM)
and is hypoxia-activated. Evofosamide was tested in a randomized phase II clinical trial
in a combination of gemcitabine versus gemcitabine alone and resulted in a significant
increment in Overall survival from 3.6 months (Gemcitabine alone) to 6 months [46].
Despite encouraging results from prior trials, evofosamide failed to significantly improve
overall survival in combination with gemcitabine in previously untreated patients with
unresectable locally advanced or metastatic PDAC in the randomized phase III
MAESTRO trial [47]. The trial reported an increase in median progression-free survival
in the combination group versus gemcitabine alone group (5.5 months versus 3.7
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months) encouraging further thought into the therapy. The trial results were mostly
disappointing except for Asian patients. Among 123 Asian patients, median OS of 12.0
months could be achieved by the addition of evofosamide to gemcitabine versus 8.5
months with placebo/gemcitabine [47]. This highlights how population diversity may
affect results in a trial and the need for therapy regimens to be tested for diverse groups
separately.

1.3.3 Second-line therapy
Most pancreatic cancers are refractory to front line therapies and hence have a dismal
prognosis. The median overall survival remains less than 12 months despite the
available front-line therapies warranting development of potent second-line therapies.
Despite 16-18% of patients undergoing a second line therapy, there are very few phase
III randomized clinical trials available for second-line treatment for metastatic pancreatic
cancer. The first phase III study came from CONKO-1 study group comparing best
supportive care with oxaliplatin, folinic acid (FA) and 5- fluorouracil (FU) and best
supportive care in patients (BSC) not responding to gemcitabine therapy [48]. The trial
had to be terminated after 46 patients due to insufficient patient accrual instead of
planned 165 patients. Median second-line survival was 4.82 months for oxaliplatin, FA
and FU (OFF) treatment and 2.30 months with best supportive care alone. Median
overall survival for first-line therapy with gemcitabine followed by OFF was 9.09 and
BSC was 7.90 months. Despite being terminated prematurely, this randomized trial
provided the first evidence of second-line chemotherapy being superior to best
supportive care alone for metastatic pancreatic cancer patients not responding to
gemcitabine [48]. After the proven benefit of second-line therapy the follow up CONKO003 trial compare the second-line OFF treatment versus FF alone for gemcitabinerefractory pancreatic cancer [49]. The study included 168 patients refractory to first-line
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gemcitabine therapy who were randomly assigned to FF or OFF. The median overall
survival and progression-free survival in the OFF group was 5.9 and 2.9 months,
whereas the FF group was 3.3 and 2 months [49]. This significant improvement by
addition of oxaliplatin in patient survival was without any clinically relevant enhanced
toxicities [49].

PDAC is characterized by an extensive desmoplastic reaction, which complicates
drug delivery and access to the tumor. To circumvent the desmoplasia novel
formulations and drug delivery mechanisms are being tested. This search was
encouraged by improved survival data seen in the NAPOLI-1 study [50]. In NAPOLI-1
trial a combination therapy of nanoliposomal irinotecan (MM-398) plus fluorouracil and
folinic acid was tested in patients with advanced metastatic PC and a prior history of
gemcitabine-based therapy, against monotherapy with nanoliposomal irinotecan or
fluorouracil and folinic acid [50]. Although the median overall survival did not differ much
between the monotherapies (nanoliposomal irinotecan4.9 months and fluorouracil and
folinic acid 4.2 months), a combination of nanoliposome irinotecan with fluorouracil and
folinic acid extended the overall survival to 6.1 months. The survival benefits were
observed with a manageable safety profile. A follow-up report from the NAPOLI-1 study
reported that overall survival benefits were maintained with no safety concerns. Oneyear overall survival rates were estimated to be 26% with the combination therapy of
MM-398 with fluorouracil and folinic acid and 16% with fluorouracil and folinic acid [50].

There are very few studies testing second-line therapy after first-line therapy of
FOLFIRINOX. Most available trials describe second-line therapy options after a first line
treatment history of gemcitabine. A retrospective study of patients with advanced
pancreatic cancer treated with FOLFIRINOX first-line therapy followed by either doublet
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or single agent as second-line therapy reported better overall survival for single-agent
chemotherapy [51]. On the contrary, an AGEO prospective multicenter cohort reported a
median survival of 18 months from the start of first-line therapy of FOLFIRINOX and a
second line therapy of nab-paclitaxel plus gemcitabine. Second-line therapy with nabpaclitaxel plus gemcitabine could achieve an overall survival of 8.8 months and median
progression-free survival of 5.1 months [52].

Although new studies have reported a survival benefit from second-line therapy,
in patients with good performance status further research is needed to device better
second-line treatment. In 2018, ASCO updated recommendations for second-line
treatment of advanced pancreatic cancer to include gemcitabine plus nanoparticle
albumin-bound paclitaxel (nab-paclitaxel) as second-line therapy for patients with firstline treatment with FOLFIRINOX and ECOG PS of 0 to 1 [45]. The recommendations
further suggest options of Fluorouracil plus oxaliplatin, irinotecan, or nanoliposomal
irinotecan as second-line therapy for patients with a history of first-line treatment with
gemcitabine plus nab-paclitaxel, ECOG PS of 0 to 1, and access to chemotherapy port
and infusion pump management services. Single-agent therapies of gemcitabine or
fluorouracil are recommended for patients with ECOG PS of 2 and who can not tolerate
more aggressive treatments [45].

1.4 Targeted therapies against PDAC
Therapies targeting specific signaling pathways or molecules associated with cancer
growth or survival are designed to target cancer cells, leaving healthy cells relatively
unharmed. Several targeting agents have been evaluated over the years against PC
alone and in combination with chemotherapeutic drugs. So far, none of the targeted
therapies has yielded a significant benefit to patient survival except EGFR family-
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targeting erlotinib, which has produced a moderate survival benefit. In the past few
years, many therapies targeting important signaling cascades in PC have failed in
randomized clinical trials with gemcitabine-based chemotherapy [25].
Targeted therapies have still to show a significant survival benefit for a collective
patient population for pancreatic cancer, but patient stratification may improve therapy
response. In a randomized phase III trial which compared gemcitabine plus erlotinib
targeted therapy with gemcitabine [53] overall survival was significantly prolonged to
6.24 months v 5.91 months for gemcitabine. Progression-free survival and one-year
survival was also higher with erlotinib plus gemcitabine. Further analysis revealed that a
subgroup of patients who developed skin rash upon erlotinib treatment had a median
survival of 12 months [53]. A skin rash can be generally considered as a positive
predictive marker for response to anti- EGFR therapy across tumor entities. However,
the molecular mechanism behind this phenomenon is still unknown. Understandably,
high molecular heterogeneity and extensive and complex stromal and inflammatory
components may be the reason behind the failure of targeted therapies in an unselected
population suffering from advanced PDAC, since molecular profile and stromal content
affect the half-life, accessibility, and metabolism of the administered therapeutic agent.

1.5 Targeting tumor microenvironment
The pancreatic tumor microenvironment is characterized by immense stroma, hypoxia,
and hypovascularization. The nature of the tumor microenvironment can be a guiding
factor for appropriate therapy regimen. Antiangiogenic targeted therapies have not been
beneficial, such as the vascular endothelial growth factor (VEGF) inhibitors , and
multikinase inhibitors with antiangiogenic activity [25]. This may be attributed to the
extensive stroma and hypovascular environment of pancreatic tumors. Exploiting the
stroma to enhance chemotherapeutic drug delivery is an attractive prospect. After
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patient survival was significantly improved with gemcitabine plus nab-paclitaxel over
gemcitabine monotherapy Secreted protein acidic and rich in cysteine (SPARC) was
proposed to enrich the concentration of nab-paclitaxel in the pancreatic cancer
microenvironment [25]. SPARC is a cancer-associated fibroblast (CAFs) produced
matricellular protein known to bind albumin and hence could enhance binding of nabpaclitaxel to tumors and increase antitumor activity. However, no association to validate
that theory could be observed [54].
The pancreatic cancer stroma contains several cell types, including inflammatory
cells, blood vessels, nerve cells, and CAFs. Pancreatic stellate cells (PSCs) are
activated fibroblasts and play a vital role in developing a pancreatic tumor[55]. Hence,
PSCs are emerging therapeutic targets. Treatment with Vitamin D ligand calcipotriol
could reverse activated PSCs to a quiescent state in a preclinical study. Since PSCs
express high levels of vitamin D receptor, their inhibition led to decreased fibrosis and
enhanced tumor uptake of gemcitabine [56]. A phase 1b study is currently underway
testing a combination of two chemotherapy drugs gemcitabine and nab-paclitaxel with all
trans retinoic acid (ATRA) in patients with locally advanced or metastatic pancreatic
cancer [57]. Emerging preclinical studies have shown that a derivative of Vitamin A,
ATRA, has the potential to remodel or suppress stroma to enhance antitumor efficacy of
drugs [57].
The stroma also comprises a variety of extracellular matrix, components,
collagen, fibronectin, laminin, and hyaluronic acid. Hyaluronic acid readily binds fluid and
increases intratumoral pressure to collapse vasculature and hence reduce drug uptake
— Pegylated recombinant human hyaluronidase (PEGPH20) in an experimental drug
that breaks up hyaluronic acid [58]. In a recent phase, II study the addition of PEGPH20
to nab-paclitaxel/gemcitabine improved progression-free survival in patients with
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metastatic pancreatic cancer with no prior treatment. Although the trial was briefly
interrupted due to thromboembolic events in the PEGPH20 group, the risk of
thromboembolic events was reduced in all patients with the use of enoxaparin
prophylaxis although the median overall survival was not improved (9.6 vs. 9.2 months)
amongst patients [58]. A retrospective analysis of the study revealed benefit to patients
with hyaluronan-high tumors (overall survival of 11.5 vs. 8.5 months, Median
progression-free survival of 9.2 months vs. 5.2 months) [58].

However, extreme caution should be undertaken while targeting PDAC stroma.
Results from mouse models and in-vitro studies are often not replicated in patient trials.
In preclinical studies in mouse models inhibition of Hedgehog signaling with
Smoothened homolog (SMO) inhibitor IPI-926 enhanced gemcitabine delivery to
pancreatic tumors by inhibiting myofibroblast growth, collagen deposition, and Tumour
vascularity [59]. However, the combination therapy of IPI-926 and gemcitabine failed
improved survival over gemcitabine monotherapy and led to the termination of the trial
due to the progression of disease in the treatment arm [59]. It was demonstrated later
that longer-term IPI-926 administration did inhibit stroma and increase vascularization
but enhanced tumor growth and metastasis in a preclinical mouse model of pancreatic
cancer. Thus, the stroma seems to have dual roles of protecting against tumor
progression and impairing drug delivery to the tumor [60]. Targeting it is a double edge
sword, and more research is required to devise strategies to target the stroma and avoid
compromising its protective role optimally.
The hypoxic nature of the pancreatic tumor microenvironment offers a
therapeutic window to target cancer cells selectively. Evofosamide failed to improve
overall survival with statistical significance in an unselected population but was
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significantly beneficial for Asian patients [47]. The study is another example of how
patient stratification can alter clinical trial result interpretation.

1.6 Immunotherapy
Immune response plays dual-opposing roles in cancer biology. On the one hand, it
regularly filters and eliminates cancerous cells, and on the other hand, it can potentiate
tumor growth by suppressing host immune response. The immune suppressive
microenvironment is one of the critical hallmarks of PC characterized by upregulation of
immune suppressive module that helps tumor cells to evade and silence the host’s
immune response [61]. Immune suppression is achieved either directly or indirectly by
cancer cells. The mechanism used by cancer cells to bypass immune clearance includes
directly expressing Teff cell inhibitory proteins on the cell surface and maintaining
immunoinhibitory cytokine profile (CXCR2, IL8) via MDSCs and T cells indirectly [25].
A long-acting pegylated form of recombinant IL10, called pegilodecakin,
stimulates the expansion of cytotoxic CD8 T cells and enhances their tumor infiltration
[62]. The increased infiltration of CD8-positive T cells has been shown to improve patient
prognosis. Hence exerts anticancer effects. Results from a previous phase I/Ib clinical
trial demonstrated a good safety/tolerability profile and sustained antitumor effects for
pegilodecakin in several cancers including pancreatic cancer [62]. A combination
regimen of pegilodecakin and FOLFOX yielded a median progression-free and overall
survival of 3.5 months and 10.2 months respectively [62]. The one-year survival rate for
the combination regimen was 47% with a disease control rate of 79%, and a complete
response rate of 11%. Following the encouraging results, a randomized clinical trial
SEQUOIA is underway comparing a combination of pegilodecakin and FOLFOX to
FOLFOX

alone

as

second-line

therapy
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patients

with
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adenocarcinoma after tumor progression during or following a gemcitabine-based
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therapy [62]. Pegilodecakin was granted the designation of an Orphan Drug for the
treatment of pancreatic cancer by the U.S. Food and Drug Administration (FDA) and
European Commission. US FDA also granted Fast Track designation for pegilodecakin
plus FOLFOX as a second-line therapy against PC.
Another new notable drug is immune modulating multicomponent complex, YSON-001. It is an emerging immune-oncology product with a broad spectrum of immune
modulating actions like activation of natural killer cells, regulation of macrophage
polarization, induction of antitumor cytokines, and suppression of regulatory T
cells. Animal studies with YS-ON-001 in multiple solid tumors, including, pancreatic
cancers have demonstrated antitumor efficacy and good safety of the product. The FDA
Office of Orphan Products Development (OOPD) has granted YS-ON-001 an Orphan
Drug designation with the potential to provide safe and effective treatment, diagnosis, or
prevention of rare diseases/disorders that affect fewer than 200,000 people in USA.

1.6.1 Checkpoint blockade

Checkpoint inhibitors or inhibitors targeting cell surface proteins that inhibit T effector
cells have been subject of several studies trying to target PDAC, but none has yielded
significant clinical benefit. Only phase I-II trials have published results with combination
therapy including PD-1, PD-L1, and CTLA-4 inhibitors in PC patients and only reported
only a small improvement over clinical trials of single-agent checkpoint blockade. αCTLA4 is a CD28 homolog and is expressed on T effector and regulatory cells and was
the first checkpoint inhibitor to be targeted in phase II clinical trial with ipilimumab which
did not yield an improvement in overall patient survival [63]. Ensuingly, several clinical
trials utilized ipilimumab in combination with chemotherapy and immune stimulators like
GVAX [64]. Additionally, a phase one trial evaluated dose escalation of anti CTLA4
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antibody with gemcitabine chemotherapy and reported safe and tolerable patient profile
[65]. These studies encouraged further clinical trials testing alternative combinations and
doses of anti CTLA4 therapy, most of which have not posted results yet.

Several phase I-II trials have since demonstrated the feasibility and potential of
improvement by adding checkpoint inhibitors to gemcitabine and/or nab-paclitaxel in the
first- and second-line treatment settings in advanced pancreatic cancer [66-68].
Available evidence suggests that combination chemotherapy and checkpoint blockade
may be more efficacious in a treatment-naïve setting compared to the second-line
therapy for patients with advanced PDAC with increasing toxicity [66, 68]. Most notable
results have been from a quadruplet regimen of gemcitabine plus nab-paclitaxel plus
durvalumab plus tremelimumab in treatment-naïve metastatic PDAC in a phase II trial
[67]. Disease control rate was reported as 100% with 6-month survival rate as 80%, and
the quadruple treatment was well tolerated. Pembrolizumab has also been tested in
neoadjuvant setting with chemoradiation for borderline resectable PDAC in phase Ib/II
trial [69]. A bifunctional anti-PD-L1 and TGFβ receptor II fusion protein have also shown
tolerability in PDAC patients suggesting the possibility of multitargeted fusion constructs
involving checkpoint blockade [70]. Selecting PDAC patients earlier in the treatment
course will also allow patients to develop a full-scale immune response with less immune
tolerance and more time to recover from immune-related adverse events.

Several ongoing clinical trials are investigating combination therapies including
checkpoint blockade in the perioperative setting to examine the efficacy of immunooncology approach in the non-metastatic setting. Although CTLA4 and PD1/PDL1 are
the most well-studied immune checkpoints, other immunoinhibitory molecules such as
LAG-3, TIM-3, and A2AR, are also being considered for immunotherapy in clinical trials
[71]. Immune cells express a CD40 at their cell surface, and its binding to the CD40
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ligand expressed on CD4+ helper T cells results in the activation of APCs (Diehl L et al.
1999). A phase I clinical trial evaluating CD40 agonist mAb therapy in combination with
gemcitabine produced a tumor response in 19% of patients with unresectable
chemotherapy naive pancreatic cancer [72]. Tumor biopsies from these patients showed
limited tumor-infiltrating lymphocytes and abundant tumor-infiltrating macrophages.
Currently, a phase I clinical trial is underway evaluating R07009789 (a CD40 agonist
mAb) combination with gemcitabine and nab‐paclitaxel for patients with resectable
pancreatic cancer.

However, there are no large-scale randomized phase III trials comparing
combination therapies with checkpoint inhibitors with the current standard of care in
PDAC. Nevertheless, ongoing studies lay some path for future studies for combination
regimens integrating checkpoint blockade.

1.6.2 Cancer vaccine
Cancer vaccines are aimed at enabling the host to generate a T cell-mediated immune
response by augmenting antigen presentation. To elaborate onco-antigens are provided
as vaccines, which when encountered by the host’s antigen presenting cells are
degraded and displayed on their cell surface and presented to effector T cells and
memory T cells. This primes the T cells to launch a cytotoxic T cell response and
developing anti-tumor immunity [72]. Some relatively well-studied antigens common in
PCs and potential targets for vaccine developments include MUC-1 (Mucin-1), MUC4
(Mucin-4), mutated KRAS and CEA (Carcinoembryonic antigen) [73, 74].
GVAX is whole cell vaccine composed of irradiated autologous pancreatic cancer cells
genetically modified to secrete GM-CSF (granulocyte-macrophage colony stimulating
factor). GM-CSF secreted by these PC cells potentially stimulates dendritic cells (DCs)
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to prime both B- and T-cells against cancer cells. GM-CSF also enables enhanced
antibody-dependent cellular cytotoxicity (ADCC) and potentiated LAK (lymphokineactivated killer) cell toxicity through IL2 secretion. Ipilimumab combination with GM-CSF
cell-based vaccine (GVAX) in a study of 30 patients resulted in enhanced median overall
survival and one-year survival over ipilimumab alone (3.6 vs. 5.7 months and 7% vs.
27%, respectively) [75]. It is notable that higher levels of mesothelin‐specific CD8+ T
cells were observed in patients in both treatment arms indicating an improved anti‐
cancer T‐cell response and had prolonged overall survival. A potential caveat to
checkpoint inhibitor therapy is lack of cytotoxic infiltrating cells and hence supplementing
it with GVAX made sense. GVAX is currently being studied in patients with resectable
pancreatic cancer in phase I/II clinical trial with or without PD-1 binding monoclonal
antibody nivolumab (NCT02451982; clinicaltrials.gov).
RAS mutations are the most common genetic mutations in pancreatic cancer. A vaccine
called TG01 developed by Targovax contains seven mutated RAS peptides, which when
injected into patients could potentiate programming of T cells to launch a cytotoxic
immune response. A phase I/II clinical trial in Norway tested this peptide-based RAS
mutation
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cancer

vaccine in pancreatic

cancer
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chemotherapy. The trial included 32 patients and showed TG01 allowed an astounding
survival advantage over 4.6 months, the median survival time after diagnosis for
pancreatic cancer patients in Europe and allowed a median overall survival of just under
three years. While these results are promising it will be interesting to explore the
potential of TG01 when combined with checkpoint inhibitors.
Immune modulation of tumor stroma
CAFs are active members of PC and facilitate tumor suppressive environment. CXCL12
is abundant in pancreatic cancer microenvironment, whereas CXCR4 is expressed on
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cancer and endothelial cells. CXCL12 also acts as a chemoattractant for hematopoietic
cells including macrophages and T cells since they express CXCR4.FAP+ stromal cells
produce CXCL12( C‐X‐C motif chemokine ligand 12 ) which binds to CXCR4 ( C‐X‐C
chemokine receptor type 4 ) and functions to promote cellular chemotaxis suggesting a
mechanism of tumor‐stromal cross‐talk [76]. Although, depleting FAP+CAFs have shown
synergy with a vaccine based or immune checkpoint-based immunotherapies in mouse
models it is not advisable to, pan‐target FAP+ fibroblasts since they are vital for normal
homeostasis and present unanimously in the human body [77, 78]. Mouse studies have
shown treatment with AMD3100 (an antagonist anti‐CXCR4 mAb) lead to T‐cell
mediated reduction in tumor growth [77]. AMD3100, commercially named Mozobil, is
being evaluated in phase I clinical trial for its potential to enhance T‐cell infiltration in the
tumor microenvironment of patients with advanced pancreatic cancer.

1.7 Precision medicine
Pancreatic cancer is a difficult disease to treat and diagnose principally due to late
diagnosis and inter and intra-tumor heterogeneity. Early diagnosis of PC can enable
better-informed decisions specific for stage and subtype of PC. The most reliable blood
test for pancreatic cancer is a serum level of CA19-9 (carbohydrate antigen 19-9) higher
than 37 U/ml. This test is 80.3% sensitive and 80.2% specific in detecting pancreatic
cancer from healthy patients. CA19-9 level can also differentiate between benign and
malignant pancreatic cancer by the specificity of 82.8% and a sensitivity of 78.2%
[79]. However, the minimum requirement for sensitivity and specificity for an early
detection test to improve patient survival and affordability if 88% and 85%. Efficient
early detection of pancreatic cancer can enhance patient survival by 30-40% [6].
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In an attempt to allow earlier and more accurate detection of PC a recent study
proposed levels of glypican-1on exosomes isolated from patient plasma. The test set up
a cut of at 7.6% glypican-1-positive exosomes and detection of benign or malignant
pancreatic cancer from healthy patients reported in the study with astounding sensitivity
and specificity of 100% [80]. Although cancer-specific exosome isolation avoids
contamination by noncancer proteins, exosome isolation from patients is difficult in
clinical practice. Genetic analysis of cell-free DNA from patient plasma is more feasible
now due to the advent of next-generation sequencing on cell-free media. A recent
study reported the diagnostic specificity of 100% and a sensitivity of 92.3% by
analyzing 54 genes concomitantly in patient samples [81].If these studies are
replicated in more extensive studies a more precise treatment regimen could be
designed to allow better patient survival.
Owing to tumor heterogeneity and limited prevalence of distinct mutations in
individual patients

patient subgrouping is difficult. An amalgamation of high-

throughput genomic technologies and advanced system biology algorithms has the
potential to utilize genomic features of pancreatic cancer and its microenvironment to
facilitate the development of treatment protocols specific to patients. Last decade saw
multiple studies subgrouping patient population resulting in two subtypes that had
clinical prognostic relevance defined as classic and basal-like. The basal-like subtype
of PC was associated with reduced median survival time, more activated stroma and
increased expression of genes such as ITGAM, CCL13 and CCL18 on marcorphages,
and members

of the SPARC, WNT and MMP families

[82]. The study utilized

microarray data for subgrouping and suggested that an RNA-derived signature
characterizes the Tumour better than the traditionally employed somatic mutations.
The first clinical trial evaluating personalized medicine over the standard of
care gemcitabine in PC was IMPaCT (Individualized Molecular Pancreatic Cancer
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Therapy) trial [83]. Patient subgroups that received targeted therapies based on tumor
mutations were; mutated homologous recombination and DNA damage repair genes
(BRCA1, BRCA2, PALB2 or ATM); amplified ERBB2; absence of KRAS mutations. None
of the patients eligible for targeted therapy could be successfully treated in this study.
UK Precision-Panc trial and the University of Toronto-initiated COMPASS trial
(NCT02750657) are other similar studies utilizing sequencing data to define a patient
population with deficient DNA repair mechanisms that could benefit from platinum-based
chemotherapy. The feasibility of this method of detection is questionable due to the
requirement of highly cellular tumors so the results would have to be critically
analyzed.
Despite the dearth of clinical trials supporting personalized therapy abundant
treatment options are available in PC to define treatment strategies specific to tumors.
Evidence suggests patients with high tumor expression of peroxisomal acyl-CoA oxidase
one could benefit from tyrosine kinase inhibitor masitinib and gemcitabine [84]. Similarly,
combination therapy with ruxolitinib (Janus kinase 1(JAK1)–JAK2 inhibitor) and
capecitabine may favor patients with systemic inflammation depicted by elevated serum
C-reactive protein (CRP) levels [85]. Another new promising study reported high tumor
levels of hyaluronic acid to suggest a potential benefit from pegylated recombinant
human hyaluronidase-based therapy [86] and lead to a biomarker-enriched phase III
trial. Similarly, ENT1 and BRAF mutations (not KRAS mutations) expression was found
to predict response with gemcitabine [18] and serine/threonine-protein kinase BRAF
inhibitors respectively. A recent study evaluated 109 patient biopsies from PDAC
patients and reported 22% of PC patients had high microsatellite instability (MSI-H).
Considering prognostic relevance of MSI in colorectal cancer Americal Society of Cancer
suggests Routine testing for dMMR or MSI-H to find patients for checkpoint inhibitor
therapy or PD-1 immune checkpoint inhibitor pembrolizumab as second-line therapy.
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The advent of organoids cultures has generated another fabulous platform for the
development of personized therapy. Pancreatic tumor organoid cultures recapitulate
the full spectrum of disease progression when transplanted orthotopically in
syngeneic mice. Tumor organoids represent tumor heterogeneity and maintains
cancer stem cells better than 2D culture and retain cell plasticities and epigenetic
changes that reflect different stages of PDAC progression. Their utilization for drug
screening is still in the nascent stage, and more studies are required to analyze if
drug response is replicated in this model as other models of PC.

Precision medicine approaches seem attractive and promising with the potential
to facilitate the development of targeted therapies against specific mutation profiles of
tumors taking into account the drug delivery, drug metabolism and adverse effects for a
particular patient. The low tumor incidence and higher variations in targetable genes
along with an implicit sampling bias due to tumor heterogeneity are possible limitations
to the development of personalized medicine.

1.8 Evaluating Therapy response with a grain of salt
Most of our preclinical studies utilize traditional cell line cultures, which often lack
the more common classical phenotype of PC. Although patient-derived xenograft studies
can recapitulate PC subtypes, it is crucial to consider the inherent capacity of the tumor
to engraft and grow when analyzing therapy response.
Our current measure of clinical trial grades drug response by RECIST criteria which
does not take the complete patient health into account and focuses on reduction in
tumor size alone. This overshadows many positive or negative effects a drug could be
making on patient health. FDA released guidelines suggest incorporation of patientreported outcomes or QOL(Quality of Life) assessments as primary, secondary, or
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exploratory endpoints in clinical trials to develop therapeutic agents (USFDA 2009). A
systematic review evaluated FDA approved cancer drugs and identified seven Trials that
used validated health care related QOL assessment in inclusion criteria. Only one drug
out of the seven retained FDA approval at the time of the study rest of the drugs
produced either no effect, or worse, or mixed effects on QOL. European Medical Agency
published similar guidelines encouraging QOL inclusion during the development of
anticancer agents. Unfortunately, there are still limited studies using QOL endpoints in
the registration of trials [87].
Lack of patient accrual and a need for evidence-based therapies warrants
evaluation in trial designs and evidence generation. Basket trials that test drugs in
different cancers that share common alterations could overcome to the lack of accrual.
Umbrella trials testing different drugs targeting different alterations in a single tumor type
could help generate more reliable evidence and better assessment of the clinical
studies.

1.9 Conclusions
Pancreatic cancer is a very deadly malignancy with many hurdles to the development of
effective therapy. There have been improvements in the last decade in our ability to
address PDAC primarily due to better perioperative care and more efficacious adjuvant
and neoadjuvant treatments. The survival following tumor resection in early stage
PDACs has almost doubled to reach 30%. Due to potent neoadjuvant therapies, patients
eligible for surgical resection have increased by nearly 50%. Although improvement in
metastatic disease is still small new combination regimens, have been beneficial to
patients. The overall survival for PDAC is still dismal, and better therapeutic
interventions are needed. Even though Immunotherapies have still to yield a
breakthrough for PDAC and approaches targeting stroma are still engulfed in

45
complexities, we have made a lot of progress in our understanding of PDAC. The
elaborate molecular makeup and unique stroma leading to tumor heterogeneity, disease
recalcitrance to therapies are much more understood. Development of new experimental
models like organoid culture and technological advances in landscaping the cancer
genome, precision medicine seems closer than ever. We need better analysis of results
from our studies and reevaluate our study designs to incorporate the new information
generated in recent years and including QOL as an endpoint in our studies to make sure
that our therapies stand the test of time.
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1.10. Figures and Legends
Fig. 1.1 Treatment guidelines for potentially curable pancreatic cancer.
Pancreatic cancer patients with borderline resectable or locally advanced disease are
stratified according to performance status (defined by Eastern Cooperative Oncology
Group score). The treatment chart represents a review of literature and guidelines from
the American Society of Clinical Oncology.
Surgical removal of the primary tumor and regional lymph nodes is usually
recommended for patients with no evidence of metastasis who meet the comorbidity
profile. Neoadjuvant therapy can also be suggested to these patients but is usually
suggested when there are radiographic findings suspicion of metastasis, but no
diagnostic evidence and comorbidity profile does not allow major surgery.
Patients that undergo surgical resection with no preoperative therapy are suggested 6
months of adjuvant treatment, which is initiated within 8 weeks of surgery, assuming
complete recovery and absence of medical or surgical contraindications. A doublet
treatment with capecitabine and gemcitabine is preferred in absence of toxicity
concerns. Alternatively, patients can be offered monotherapy with gemcitabine or
fluorouracil plus folinic acid. Adjuvant chemoradiation may be suggested to patients (no
preoperative therapy) with microscopically positive margin (R1) and/or metastasis in
lymph nodes after 4 to 6 months of systemic adjuvant chemotherapy.
Patients who receive neoadjuvant treatment 6 months of total adjuvant therapy
(including preoperative regimen) is recommended as per doctors’ decision.
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Fig. 1.1
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Fig. 1.2 Treatment guidelines for borderline resectable or locally advanced
pancreatic cancer.
Pancreatic cancer patients with borderline resectable or locally advanced disease are
stratified according to performance status (defined by Eastern Cooperative Oncology
Group score). The treatment chart represents a review of literature and guidelines from
the American Society of Clinical Oncology.
An induction chemotherapy (initial systemic therapy) is recommended for most patients
with ECOG PS of 0 or 1 with favorable morbidity profile. Due to absence of randomized
clinical trial data physicians may offer therapy on the basis of treatment of a metastatic
PDAC. chemoradiotherapy or stereotactic body radiation therapy may be offered.
chemoradiotherapy or stereotactic body radiation therapy may also be suggested to
patients in case of local disease progression after induction therapy but lack of evidence
for systemic spread and ECOG PS less than equal to 2. patients who have stable
disease or responded to 6 months of induction chemotherapy but developed
unacceptable chemotherapy-related toxicities can also be given chemoradiotherapy or
stereotactic body radiation.
Patients who do not benefit from first-line treatment should be offers treatment as per
metastatic cancer guidelines.
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Fig. 1.3 Treatment guidelines for metastatic pancreatic cancer.
Pancreatic cancer patients with metastatic pancreatic are stratified according to
performance status (defined by Eastern Cooperative Oncology Group score). The
treatment chart represents a review of literature and guidelines from the American
Society of Clinical Oncology.
First-Line Treatment
For patients with ECOG PS of 0 to 1 and favorable comorbidity profile FOLFIRINOX
(leucovorin, fluorouracil, irinotecan, and oxaliplatin) is recommended when there is
access to infusion pump. Gemcitabine plus NAB-paclitaxel is recommended for patients
with an ECOG PS of 0 to 1 and a relatively favorable comorbidity profile.
Whereas for patients who have an ECOG PS of 2 and/or a comorbidity profile that
disqualifies more aggressive regimens monotherapy with gemcitabine is recommended
which may be supplemented with either capecitabine or erlotinib as per the doctor’s
decision.
Patients with an ECOG PS ≥ 3 or with poorly controlled comorbidity profile should be
offered cancer-directed therapy only on a case-by-case basis with emphasis on
optimizing supportive care.
Second-Line Treatment
Routine testing for dMMR or MSI-H is recommended, for patients for checkpoint inhibitor
therapy consideration. If tested positive a second line therapy with pembrolizumab may
be suggested.
FOLFIRINOX treated patients can be given Gemcitabine plus NAB-paclitaxel as secondline therapy if patients maintain an ECOG PS of 0-1, a relatively favorable comorbidity
profile and can sustain aggressive medical therapy. Fluorouracil plus nanoliposomal
irinotecan, or irinotecan can also be suggested for such patients.
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gemcitabine plus NAB-paclitaxel treated patients can be advised Fluorouracil plus
oxaliplatin as second-line therapy if patients can support aggressive therapy and have
an ECOG PS of 0 to 1, and relatively favorable comorbidity profile.
A second-line therapy of Gemcitabine or fluorouracil can be considered if patients have
an ECOG PS of 2 or a comorbidity profile that disqualifies more aggressive regimens.
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Fig. 1.3
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CHAPTER 2: MATERIALS AND METHODS
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2.1 Cell culture
Capan1 and SW1990 cell lines were obtained from ATCC and were cultured in high
glucose DMEM medium supplemented with 10% FBS and 1% penicillin-streptomycin.
Cultures were routinely inspected for mycoplasma contamination and phenotypic
variation. Cell lines were incubated in a humidified atmosphere at 37ᵒC with 5% CO 2.
Afatinib was purchased from Selleck Chemicals, TX, USA, while gemcitabine was
obtained from Sigma Aldrich. Afatinib and gemcitabine were reconstituted in PBS as per
manufacturer’s instructions.

2.2 Isolation of CSC/side population
The side population/CSC population was sorted using BD FACS Aria (BD Biosciences)
after staining cells as shown previously [88]. One million cells in 1 mL of culture medium
were stained with Hoechst 33342 (AnaSpec Inc., Fremont, CA, USA) (5 µg/ml) for one h
at 370C. Verapamil (Sigma) control staining was performed at a final concentration of 50
µM to set up side population gating.

2.3 Tumorsphere assay and drug treatments
An in vitro tumorsphere assay was performed using CSC and non-CSC populations
isolated from SW1990 and Capan1 cells. The tumorsphere assay was performed as
shown previously [89]. Briefly, cells were subjected to drug treatments and then seeded
in low-attachment 24-well plates in DMEM/F12 (Invitrogen, Grand Island, NY, USA)
medium supplemented with 1% B27 supplement, epidermal growth factor (EGF) (20
ng/mL), and basic fibroblast growth factor (bFGF) (10 ng/mL). After seven days, spheres
were viewed under the microscope, counted and photographed.
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2.4 RNA isolation and quantitative real-time PCR (qRTPCR)
For quantitative mRNA analysis, RNA was isolated using the QIAGEN RNeasy mini kit
(Qiagen, Valencia, CA, U.S.A.), and its concentration was determined using a NanoDrop
ND 1000 Spectrophotometer. cDNA was synthesized using oligo(dT)18 primer, and
SuperScript II RNase reverse transcriptase (Invitrogen). qRTPCR was performed for
genes that were screened by PCR array analysis.

2.5 Transfection experiments
SW1990-SP PC cells (0.5×106) were seeded in a 6-well plate and incubated for 24 h.
After

24 h, cells

were transiently transfected with two independent siRNA

oligonucleotides specific for human EGFR (100 pmol) (Origene) and FOX2 (100 pmol)
(Origene) using lipofectamine transfection reagent for 72 h. Non-targeting (siRNAs)
oligonucleotides were used as transfection control. After 72 h of incubation, cell lysates
were isolated using RIPA buffer and subjected to western blotting and protein
expression analysis.

2.6 PC organoid development from LSL-KrasG12D/+; Pdx-1-Cre (KC), and LSLKrasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre (KPC) mouse tumors
In brief, tumor organoids were established from KC and KPC autochthonous mouse
models and subjected to enzymatic digestion with 0.012% (w/v) collagenase XI (Sigma)
and 0.012% (w/v) dispase (GIBCO) in DMEM media containing 1% FBS (GIBCO); the
extracts were embedded in growth factor-reduced Matrigel (BD Biosciences) [90].
Organoids

were maintained and cultured in complete AdDMEM/F12 medium

supplemented with HEPES (Invitrogen), Glutamax (Invitrogen), penicillin/streptomycin
(Invitrogen), B27, Primocin (1 mg/ml, InvivoGen), N-acetyl-L-cysteine (1 mM, Sigma
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Aldrich), mouse recombinant Wnt3a (100 ng/ml, EMD Millipore), human recombinant
RSpondin1 (1 μg/ml, PeproTech), Noggin (0.1 mg/ml, PeproTech), epidermal growth
factor (EGF, 50 ng/ml, PeproTech), gastrin (10 nM, Sigma), fibroblast growth factor 10
(FGF10, 100 ng/ml, PeproTech), Nicotinamide (10 mM, Sigma), and A83-01 (0.5 mM,
Tocris Biosciences).

2.7 In vivo xenograft mouse model and treatment strategy
Luciferase-labeled Capan1 cells (0.25x106 cells) were injected in vivo, orthotopically in
the head of the pancreas in athymic nude mice. The successful injection was verified by
the appearance of a fluid bubble without signs of intraperitoneal (IP) leakage. The
abdominal wall was sutured, and the skin was closed with wound clips. Following tumor
development in these mice (4 weeks after injection), we started therapy. Afatinib was
administered orally (15 mg/kg/body weight) 45 times a week, and gemcitabine was given
IP (50 mg/kg/body weight) twice a week. Following three weeks of treatments, mice
were euthanized, and primary tumors and other organs were harvested for further
analysis.

2.8 Immunoblot analysis
Western blot analysis was performed as described previously [91]. The blots were
incubated with the following primary antibodies: pEGFR, EGFR, pHer2, Her2, pERK,
ERK, FOXA2, SOX9, CD44V6, CD44, EpCAM, ALDH1, ABCG2, pFAK, FAK, NANOG.
Secondary antibodies used were Rabbit, 1:1000; Cell Signaling Technology (CST)) and
-Actin (mouse, 1:5000; Sigma Aldrich).

57
2.9 Confocal immunofluorescence microscopy
Immunofluorescent labeling of cells was carried out by plating them at low density on
sterilized coverslips. Cells were washed with 0.1mol/L HEPES containing Hank’s buffer
solution followed by fixation with ice-cold methanol at -20°C for 2 minutes. Blocking was
performed with 10% goat serum for at least an hour to avoid nonspecific staining.
Primary antibody incubation was performed overnight at 4°C followed by PBS washes.
The fluorescent conjugated secondary antibody was incubated for 1 hour at room
temperature in the dark. The coverslips were inverted and mounted with Vectashield
DAPI. Microscopic slides were prepared from formalin-fixed, paraffin-embedded samples
of tumoroids (tumor organoids) and orthotopic tumors, de-paraffinized using xylene, and
hydrated by a graded series of ethanol washes. Antigen retrieval was performed by
microwave heating in 10 mmol/L sodium citrate buffer (pH 6.0) for 10 min. Sections were
then probed with primary antibodies (1:200) diluted in PBS and incubated overnight at
4°C. After washing twice with PBS, secondary antibodies (1:250) were added for one
hour. Slides were again washed twice with PBS and images were taken under a
confocal microscope.

2.10 Immunohistochemistry
Microscopic slides were prepared from formalin-fixed, paraffin-embedded samples of
orthotopic tumors, de-paraffinized using xylene, and hydrated by a graded series of
ethanol washes. Antigen retrieval was performed by microwave heating of slides in 10
mmol/L sodium citrate buffer (pH 6.0) for 15 min. Endogenous peroxidase activity was
quenched with 3% H2O2 in PBS for 30 minutes. After washing slides were subjected to
30 minutes of blocking with Vectastain normal horse serum to block nonspecific binding.
Sections were then probed with primary antibodies (1:200) diluted in PBS and incubated
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overnight at 4°C. Sections were then washed and incubated with horseradish
peroxidase-labeled secondary antibody for 30 minutes. Slides were washed and
incubated with ABC solution (Vector Laboratories). The final reaction with 3,3’diaminobenzidine reagent (DAB) was carried as per manufacturers instructions to
develop color. He slides were subsequently washed with water and counterstained with
hematoxylin. This was followed by the dehydration process using increasing alcohol
gradients

and

mounted

with

Vectamount

permount

mounting

media(Vector

Laboratories).

2.11 Statistical analysis
Statistical significance was assessed using two-tailed t-test and ANOVA tests using
GRAPH PAD Prism software. All experiments were carried out in triplicates . For
composite scoring of tissue array percentage of a cell stained (0-100%) were multiplied
with the intensity of the stain (1-3) to achieve a composite score. Differences between
the groups were considered significant when the p-value was less than 0.05.
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CHAPTER 3: THREE-DIMENSIONAL ORGANOIDS AS PRECLINICAL
MODELS

A part of this chapter has been published in as a review titled: Concise Review:
Current Status of Three-Dimensional Organoids as Preclinical Models [92]
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3A. Review of Literature

3A.1 Introduction
The past decade has seen tremendous development in disease modeling and
generating accurate experimental models that mimic biological processes, from coculture techniques to 3D printed scaffolds and organoid culture [93-97]. Generating
precise experimental models is essential for understanding basic biology, disease
development,

and therapy responses, but generating the complex biological

environment of an organ to study development, or tumor to study progression and
therapy, is nevertheless a challenging task.
Over time, various tools have been employed to generate experimental models
that can recapitulate human biology (or at least some of its properties). Conventional
cultures have included growing transformed cells derived from biological tissues in
monolayer cultures. These are easy to culture and amenable to experimental
modifications. Though these transformed cell lines allow study of human cancer cells,
because they have spent years in vitro since establishment, they tend to acquire an
undefined and complex mutational background [98]. Monolayer cultures are also twodimensional (2D) and do not represent the tissue architecture and cellular heterogeneity
found in tissues or tumors of their origin [98, 99].
Animal models make for some of the drawbacks of 2D cultures since they include
stroma, vasculature, and immune components. They can, however, be engineered to
generate transgenic disease models to recapitulate pathogenesis using molecular
biology tools and breeding strategies. Another experimental use of these animals is
generating patient-derived xenografts or tumor xenografts. These models are extremely
powerful but are also resource intensive and time-consuming to develop. Moreover, the
genomic profile of animal models does not exactly march with human profiles [100].

61
The first reports that described 3D culture systems discussed models that allow
for long-term expansion of single mouse adult intestine [101], stomach [93], liver [102],
and pancreas [102]. The first breakthrough experiments in the field of 3D culture were
performed using Lgr5+ stem cells or intestinal crypt cells in 2009 [101]; this study
demonstrated that stem cells could be used to generate stable, near-physiological
epithelia when supplied with growth factors and proteins close to endogenous stem cell
niche components [101].
The idea of a system that recapitulates a holistic microenvironment of normal
biology ex vivo while proving experimental ease and feasibility of cell lines lead to the
development of 3D culture methods. Cellular behaviors in vivo depend on environmental
signals and contacts with neighboring cells and the extracellular matrix. 3D cultures
allow for these signals to some extent and hence serve as an experimental system
closer to normal biology.
Organoid 3D-cultures can be formed using a variety of source materials, from
spheroids derived from sorted cells to tissue segments, to whole organ explants [96, 97,
101, 103]. Due to the differences in source material used and the 3D environment and
scaffold provided, there are differences in the types of cultures generated, and it is this
diversity that poses a challenge to define these organoids. Although the definition of
organoids is still evolving, for the purposes of this review, we use the term to address
cultures that recapitulate in vivo architecture, maintain stem cells or progenitor pool, and
multi-lineage heterogeneity.
Several approaches used to study a broad range of developmental and cellular
processes have been comprehensively covered in reviews elsewhere [103, 104]. Our
focus herein is on the most recent developments in organoid culture for major organs
and cancers, including representation of their microenvironments and stem cells (niches)
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on an appropriate scaffold. We also present our views on their implications on the
development and testing of therapeutics.

3A.2 Perquisites to Organoid Generation: Where do we start?
Organoids have become a powerful tool for research and are becoming common in
everyday lab practice, but there are certain key pieces of information necessary to
consider before organoid development. Paramount among these are the selection of
appropriate sources of organ or cells (iPSCs, Adult SCs, Organ chunks, embryonic SCs,
etc.) and appropriate protocols that employ necessary growth factors and morphogens.
The correct matrices essential for multiple stages of organoid development must also be
determined. Then, once organoids develop, media composition must be determined to
maintain structure and retain the functional characteristics of the organ of intent. In the
following sections, we discuss such considerations and how they affect the generation of
organoids.

3A.3 Source Tissue: Beginning decides the end
Organoids can be cultured from embryonic stem cells (ESCs), adult stem cells (AdSCs) ,
human-induced pluripotent stem cells (hPSCs), and tissue fragments. Development of
hPSCs and human embryonic stem cells (ESC) culture techniques in parallel to 3D
culture systems has helped researchers recapitulate the successful differentiation and
development of endodermal (lung, stomach, liver, small intestine) and ectodermal (brain
and retina) tissues in vitro, and has opened up new avenues for further research (Fig.
1).
Recent attention has focused on using hPSCs or patient tissue samples via the
process of reprogramming adult somatic cells into induced pluripotent stem cells (iPSCs)
by ectopic expression of pluripotency transcription factors [95]. These cells are then
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transformed into organoids by using the signaling pathways involved in modeling germ
layer formation and induction of organ primordia,Wnt, EGF, Retinoic acid, and
TGFβ/BMP. iPSC-derived organoids have been generated from brain [105], lung [95],
intestine [106], stomach [107], eyes [108], and kidney [109]. Organoids have also been
generated using adult stem cells or adult primary tissue and then expanded long-term in
vitro. These studies also built upon the available knowledge of stem cell niche
requirements and generated their media with a base composition of Wnt, RSPONDIN,
EGF, and Noggin, and include mouse and human pancreas, liver, intestine, stomach,
prostate, fallopian tube, and salivary gland organoids [110]. Such availability of different
sources determines the necessary media components.

3A.4 Importance of Matrix Selection
Once selected, it is important to provide an appropriate microenvironment for source
tissue. The most common 3D environment used in the formation of organoids are
hydrogels, such as Matrigel, that contain gelatinous mixtures of extracellular matrix
components, including laminin and collagen [111, 112]. For instance, a primary culture of
pancreatic ductal cells has been made possible by seeding stem cells or tissue
fragments in Matrigel as submerged cultures that support the growth of epithelial cell
cultures [93], whereas long-term organoid cultures that include both epithelial and
mesenchymal components have been successfully performed using an air-liquid
interface method [93, 100]. This method uses collagen gel containing trans-well
suspended in media and direct exposure to air. Tissues or cells are mixed with Matrigel
and layered over the collagen, where they develop organoids. The first study to engage
this method developed a primary mouse intestinal culture that allowed for sustained
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intestinal proliferation and multi-lineage differentiation. Such cultures lasted from 30 to
>350 days using neonatal tissue as starting material [113]. This allowed recapitulation of
both the cellular myofibroblast architecture and the rigorous Wnt and Notch-dependent
stem cell compartment. These organoids could then be transformed into their oncogenic
counterparts by genetic manipulation [114].
A recent study reported that matrix stiffness has an impact on organoid growth
and stem cell signaling in intestinal organoids. The authors reported employing a
synthetic scaffold design, using a polyethylene glycol backbone with a more consistent
and chemically defined synthetic hydrogel that allowed stem cell expansion and
organoid formation [115]. Similarly, artificial scaffolds can be created by attaching
microenvironmental signals such as ECM components and cell-to-cell interaction
proteins to an artificial scaffold [115]. Various techniques may be tried, such as
microcontact printing, which directly deposits ECM onto a partially polymerized hydrogel
substrate using soft lithography techniques [116]. Nutrition and gaseous exchange are
two other aspects affected by the matrix. Human bronchial epithelial cells(HBECs)
embedded within Matrigel, for example, organize into spheroids that contain cuboidal
epithelial cells, whereas HBECs plated on top of the Matrigel layer self-organize into
tubular structures that undergo branching and budding.

3A.5 Media requirements and properties of generated Organoids

Developmental biology studies have long revealed that the morphogen gradient decides
cell fate during embryo development. 3D organoids have been used to intelligently apply
that knowledge when deciding on which media components will be necessary for a
specific organoid generation. We will further describe media requirements and the

65
rationale behind several organoids that have been developed and used for modeling
disease.

Brain Organoids
3D brain tissues or mini brains can now be generated using pluripotent stem cells (PSC).
These tissues, also called cerebral organoids, are created by first driving pluripotent
stem cells to a neural progenitor lineage and then providing a supportive 3-dimensional
microenvironment for them, where they can self-organize spontaneously into the early
embryonic brain [117]. A recent study reported the successful formation of brain
organoids from human pluripotent stem cells, comprising the timely amalgamation of
several previously published methodologies to accomplish successful differentiation of
PSC into neural progenitors and progress further down the neural lineage [105, 118].

Mototsugu Eiraku reported in 2008 a special 3 D culture condition that showed
differentiation of embryonic stem cells into embryoid bodies and then into self-organized
apicobasal polarized cortical tissue [119]. He used FGF, Wnt, and BMP factors to model
his 3D aggregate cultures. Since then, multiple reports have built upon his methodology
[97, 105, 117, 118, 120-122]. A more recent study reported the development of
heterogeneous brain organoids, naming them “cerebral organoids.” They used a similar
approach and differentiated embryonic cells to neuroectoderm and then incubated them
in differentiation media in Matrigel, finally allowing them to grow and form cerebral
organoids in differentiation media supplemented with retinoic acid as Matrigel droplets in
a spinning bioreactor [117].

A recent report described a novel developmental model of 3D brain-like tissue by
applying an interdisciplinary approach, involving seeding cells within a biomaterial
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scaffold to assemble microstructural features representative of native tissue [118]. This
technique sought to recapitulate the structural features formed during development of
the forebrain cerebral cortex, including gray matter (containing cell bodies) and white
matter (containing neuronal axons). The study used silk protein to design scaffold, which
provided spatial separation of cell bodies and neural processes. This lead to the
development of a suitable matrix for growth of 3D compartmentalized neuronal networks
that could recapitulate the properties of the native cortex and to establish the suitable
conditions for neural growth [105, 122].

Lung Organoids
During embryonic development, the endoderm produces a primitive gut tube along which
the lung, thyroid, and organs lining the gastrointestinal (GI) tract emerge. The lung arises
from cells expressing the transcription factor NKX2.1 (TTF-1; Thyroid Transcription
Factor 1) in the ventral wall of the anterior foregut endoderm [123]. Hence, current
available protocols include discrete steps to differentiate human pluripotent stem cells
(hPSCs) through an initial definitive endoderm (DE) specification, then the anterior
foregut endoderm (AFE), and finally into ventral anterior foregut endoderm (VAFE) and
NKX2.1 expressing lung progenitors [123, 124]. Each step uses stage-specific growth
factors to recapitulate the signaling pathways involved in lung development. Of
importance, since organoids develop from tissue-specific stem cells or progenitors,
hPSC differentiation into these cell types has been employed as a strategy to develop
organoids.
Lung organoids are mostly derived from primary respiratory cells and cell lines [123,
125]. A recent study demonstrated that primary basal cells harvested from mouse and
human

lungs

could

self-organize

into

organoids,

called

tracheospheres

or

bronchospheres, when cultured in a 3D ALI [125]. These organoids are derived from
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basal cells expressing p63 and NGFR, which proliferate to establish a layer of basal
cells in a spherical organization, and that are covered on the luminal side by a second
layer of a differentiated goblet and ciliated cells.
Thus far, two studies have reported the generation of lung organoids in vitro from
hPSCs. The first showed that purified Carboxypeptidase M (CPM) expressing cells in 3D
conditions, supplemented with alveolar-related growth factors and human lung
fibroblasts, produced alveolar epithelial spheroids. These spheroids contained cells
expressing NKX2.1 and CPM, as well as differentiated cells that stained positive for
AQP5 (Aquaporin 5) and SFPTC (Surfactant Protein C), markers of type 1 and 2
alveolar epithelial cells (AEC1s and AEC2s), respectively [126, 127].
The second study performed a step-by-step differentiation of hPSCs and reported
multi-lineage organoids with epithelial and mesenchymal components. By stimulating the
Hedgehog (HH) signaling pathway during spheroid generation, the authors could
enhance NKX2.1 expression and expand spheroids in media containing FGF10 [123,
126]. This allowed VAFE spheroids to grow into more complex structures that the
authors called human lung organoids (HLOs). HLOs persisted in culture for over 100
days and developed organized proximal airway-like epithelial tubules containing
numerous cell types found in the native airway epithelium, including basal, ciliated, and
club cells and that were surrounded by smooth muscle actin (SMA)- expressing
mesenchymal tissue maintaining early bi-potent alveolar progenitor cells [123, 126, 127].
In our lab, we explored these principles and generated lung organoids from genetically
engineered mouse model with mutant KRAS and p53 deletion. We used a media
composition that favors maintenance of stem cells and lung development by including
factors such as FGF4, Noggin, and CHIR99021 (Glycogen Synthase Kinase 3 Inhibitor).
These organoids generate histological structures similar to lung tumor and proved to
grow stably in culture.
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Mammary Organoids
Mammary acini contain extensive stromal and extracellular matrix compartments, the
composition of which changes depending on signals such as growth factors and
hormonal changes. Even monolayer cultures of mammary epithelial cells can form
functional tubular structures when provided with the required environmental cues; for
example, upon transplantation into the gland-free fat pads of mice [128]. It would be
logical to infer that either the systemic factors or cellular microenvironment that
surrounds the mammary epithelial cells confer the cues that drive functional
differentiation of mammary epithelial tissue, suggesting the importance of providing a
matrix to the cells in culture that resembles their biological ECM. Michalopoulos and
Pitot (1976) were the first to use floating collagen gels to provide an extracellular
environment to hepatocytes that could maintain their functional and morphological
identities in culture for a short period [129]. Emerman and Pitelka further adapted this
idea in the 1970s, and in 2013, Mroue and Bissell cultured mouse primary mammary
epithelial cells that retained functional differentiation using both floating collagen-I (Col-I)
gels and laminin-rich ECM gels (lrECM) [128, 130]. Mammary epithelial cells grown on
floating collagen gels were found to reorganize and form secretory structures that
express milk proteins de novo.
Another observation made by Mroue et al. highlighted the significance of the
composition of ECM provided in deciding the fate of cells in culture [130]. They reported
that mammary organoids, when cultured on floating collagen gels, contained mammary
epithelial cell (MECs) clusters, which exhibit basoapical polarity and cellular junctions,
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and expressed the milk protein β-casein. These lacked expression of whey acidic protein
(WAP) and did not form luminal alveolar structures, both essential features of the
mammary gland [130].
In a recent report, Linnemann et al. published alternative 3D culture conditions for
the expansion of TDLU-like structures (Terminal Ductal lobular Units) from primary
human cells [131]. The advantage of this method is that it includes conditions that
support the growth of single cells at high efficiency. Its drawbacks are that it incorporates
chemical agents (Rho-associated protein kinase inhibitor, forskolin) and serum that
perturb intracellular signaling in nonphysiological ways. The relative merits and failings
must be carefully considered before deciding the appropriate model system to use in the
future study.

Liver Organoids
Two epithelial cell types, hepatocytes, and ductal cells, chiefly compose liver [132].
Hepatocyte-like cells have been generated by differentiating human embryonic stem
(hES) cells and human induced pluripotent stem (hiPS) cells. However, because of the
genetic and epigenetic aberrations that occur during the reprogramming process [133,
134], the use of these models for translational research and regenerative medicine [135]
remains limited. Generation of liver organoids overcomes these limitations; the
organoids are generated by using the Wnt, BMP, RA, HGF, and FGF signaling pathways
that regulate the embryonic development of the liver.

Liver organoids were generated by mixing stem cells and/or tissue fragments
with Matrigel and providing growth factors like EGF, HGF, FGF, and RSPO1. Such
conditions allowed liver cells to self-organize into organoids resembling embryonic liver
buds [136]. These organoids were Keratin positive and expressed progenitor cell

70
markers. The authors also reported that the generation of human liver organoids
requires inhibition of TGFβ signaling. Replacement of Notch and RSPO by
dexamethasone and BMP also allowed differentiation of these organoids into
hepatocytes [136].

Pancreatic Organoids
Two functionally distinct compartments make up the pancreas: ductal and acinar cells
consist of the exocrine compartment, and the Islets of Langerhans make up the
endocrine compartment. The genes and molecular pathways regulating the embryonic
development of the two compartments are evolutionarily conserved and include FGF,
HGF, Wnt, BMP, RA, and TGFβ. These pathways promote survival, proliferation, and
migration of the progenitor pools that generate these two distinct compartments [93, 101,
102, 137, 138]. Developmental studies and knowledge acquired from 3D cultures of the
stomach and intestine allowed researchers to culture, expand, and differentiate mouse
and human primary pancreatic

tissue

[101-103]. Providing an ECM and a

microenvironment that includes growth factors essential during development of pancreas
(Noggin, EGF, FGF and R-spondin-1(Rspo1)) is necessary for the long-term expansion
of the adult pancreatic tissue in these 3D culture systems [102]. Using a similar
approach, we developed murine pancreatic organoids from wild-type C57BL/6 murine
pancreas which show histology similar to pancreatic ducts (Fig2.). A similar approach
was also used to generate models to study pancreatic tumors and for which tumor
organoids were generated from KC (Kras;PdxCre) and KPC (Kras;p53;PdxCre)
autochthonous animal models for PDAC and were shown to histologically represent
PDAC progression.
Another study used neonatal wild-type C57BL/6 mice pancreatic tissue to
generate organoids by the air-liquid interface culture method. These grew progressively
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for more than 30 days as cystic structures carrying an epithelial layer and surrounded by
fibroblasts [139]. α-smooth muscle actin–positive (SMA+) stromal cells were observed in
association with these cystic epithelial organoids, which could be readily infected with
adenovirus and were predominantly comprised of E-cadherin–positive (E-cad+) and
Pdx1+ ductal epithelium with PCNA+ proliferating cells. [93, 140]. Somatostatin and
insulin were also found to be expressed in rare, islet-like regions not always associated
with ductal structures; sporadic immunoreactivity was also reported for glucagon and
amylase occasionally.
Intestinal organoids
A submerged Matrigel model [101] allowed a culture of Lgr5+ cells or crypt fractions to
be cultured into exclusively epithelial organotypic intestinal structures, also referred to as
enteroids. Growth factors that simulate the paracrine signaling environment surrounding
stem cells were supplemented in a media concoction for these enteroids, and 3D mouse
and human organoids were generated [101]. Intestinal organoid or enteroid generation
by this method requires Wnt stimulation with Wnt3A, epidermal growth factor (EGF), the
BMP antagonist Noggin, and the Wnt agonist R-Spondin1 to be supplemented in the
media [141]. Another recent method uses collagen-based, air-liquid interphase to
generated 3D organoids which incorporate epithelial and mesenchymal components
[142]. This system uses collagen and Matrigel together to grow organoids on air-liquid
interphase, without the requirement of exogenous growth factors, and the resulting
organoids were found to contain both epithelial and mesenchymal compartments and
could be cultured for >60 days [143]. Primary intestinal and tumor organoids have been
generated using both these methods and are currently being used for a variety of
applications, from toxicology studies to drug screens and disease modeling [143].
Epithelial enteroids propagated from mouse or human Lgr5+ cells or intestinal
crypt fractions follow an easy-to-follow method of generation and expansion. Enteroids
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typically constitute cystic epithelium with an inward-facing apical side and a progenitor
pool containing crypt-like invagination [144]. All intestinal lineages have been observed
in these cultures, which could be serially passaged and expanded. To enhance
efficiency and include multiple biological parameters, several refinements have been
made to this system, including Wnt3A withdrawal used to facilitate differentiation; the
use of the Rho kinase inhibitor Y-27632 to avoid anoikis during tissue preparation,
passaging and revival; using GSK3β kinase inhibitors and valproic acid to promote a
stem-like state; and myofibroblast feeder layers to replace Wnt and R-spondin from
medium [143]. Isolation of these enteroids follows a general scheme of mincing tissue or
intestine and subjecting it to enzymatic digestion. The digested fraction is centrifuged,
and intestinal crypts are isolated from it. These crypts are then embedded in Matrigel
and seeded in submerged cultures [101].
Ovarian and Fallopian Tube Organoids
Fallopian tube model systems have traditionally facilitated ovarian development and
ovarian cancer studies, and a similar trend was followed in 3D culture systems. Recent
studies have demonstrated the existence of adult stem cells in the human fallopian tube
epithelium that gives rise to differentiated epithelial cells in complex 3D organoids in vitro
[145]. These organoids were reported to recapitulate the in vivo tissue architecture; they
could depict growth and be maintained in culture long term. The culture protocol and
growth conditions are similar on a gross scale to the intestinal tract, skin, liver, and
ovary. Active Wnt signaling works towards maintaining the stem cell population in these
organoids, achieved by activating Wnt target genes Lgr4, 5, and 6, all of which are a
subfamily of leucine-rich, repeat-containing G protein-coupled receptors that can
strongly amplify Wnt signals. The R-spondin family of proteins also acts as an Lgr
receptor agonist. Similarly, the growth capacity of organoids is modulated by Wnt3A and
R-spondin-1 (RSPO1) [145]. This organoid model faithfully mimics the normal physiology
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and anatomy of the human fallopian tube and provides a platform for future
investigations into the regulatory mechanisms involved in its cellular renewal and
pathology. Overall growth rates for these organoids during long-term culture remained
constant, with passaging every 2–3 weeks. This method yielded expandable, stable
organoid cultures in all healthy tissue samples, with minimal variations in sphere
formation potential and growth rate between donors or between distal and proximal tubal
regions
Prostate Organoids
The prostate gland produces seminal fluid in the male reproductive system and is
composed of a pseudostratified epithelium of luminal, basal and rare neuroendocrine
cells. Additionally, prostate development and homeostasis, as well as prostate cancer
initiation and progression, requires androgen receptor (AR) signaling [146]. Most in vitro
studies are performed using cell lines, and most of these do not have an intact AR
signaling pathway, making them poor models to represent healthy prostate and cancer
tissue [146, 147]. Lack of suitable in vitro model systems is an obstacle for prostate
cancer research. Although robust in vivo models are available, these are often
expensive, time-consuming, and technically daunting.
Another study by Chua et al. recently demonstrated the development of
organoids from sorted luminal cells, but these 3D cultures with limited growth potential
[148]. Although these were AR-responsive, the medium used in this study included
undefined components like fetal calf serum and had a plating efficiency of 0.2% to 0.3%
[147, 148].
Drost et al. developed a testosterone-responsive prostate organoid culture
system by adapting and optimizing the culture conditions previously employed to
establish mouse and human colon and intestinal organoid cultures. Different compounds
and growth factors, including epidermal growth factor (EGF), Noggin, and R-spondin 1,
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were added to the generic organoid medium to allow for the establishment of long-term
mouse and human prostate organoid cultures. These submerged prostate organoid
culture systems contain multipotent progenitor cells in both the luminal and basal
lineages that can be propagated long term. AR signaling is indispensable for organoids
to functionally recapitulate prostate and was maintained in these organoids. This study
concluded that organoids derived from human or mouse prostate cancer recapitulate
genetically and phenotypically the tumor from which they were derived [147].
This method was further adapted by our lab to generate prostate and prostate
cancer organoids from mouse tissues (Fig. 2). The main procedure involves dissection
and digestion of tissue, followed by subsequent embedding, plating, and organoid
passaging. We plated organoids are plated in Matrigel and cultured them in a defined
prostate culture medium, after which they were sub-cultured and frozen. These
organoids

can be cryopreserved once established and are genetically and

phenotypically

stable.

Prostate

tumor

organoid

media

includes

DMEM/F12

supplemented with B27, N-acetylcysteine, EGF, Noggin, R-spondin 1, A83-01, and DHT
[147, 149].

3A.6 Limitations: Need for Intervention

The potentials organoids hold for future study and use are innumerable, but they present
some limitations, as does any technology. The organoids established so far need to be
characterized and studied to the extent that exact recapitulation of in vivo development
is possible. Tissue maturation is one of the limitations associated with retinal and
cerebral organoids, where early events display intact organization, but the organized
tissue fails to develop into a functionally mature organ. However, intestinal organoids
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produce Lgr5+ stem cells, implying movement towards a mature intestine [101]. One
solution to the maturation problem may be by growing a mature organ followed by
transplantation. Another limitation of organoids is non-vascularization due to limitations
in nutrient supply, which may be solved by spinning bioreactors that provide a better
nutrient exchange. Vascularization may also be achieved by co-culturing with endothelial
cells that can generate vascular-like networks. Some researchers have generated hybrid
cultures with organoids to incorporate different cell types to generate more insightful
models.[150]
Another limitation to organoid cultures is the limited presence of stromal
components, including immune components, and this hinders organoid use in modeling
inflammation and drug penetration studies [151]. Organoid cultures are also
heterogeneous with no reliable means of synchronizing size shape and viability. This,
unfortunately, leads to complications in data analysis and study design. Although all
these limitations stand in the way of organoid applications, they can be overcome by a
better understanding of ECM components and live cell imaging techniques that facilitate
the analysis of the co-cultures or hybrid cultures of these organoids.

3A.7 Prospective application: Making the most of tremendous tool
Normal organoids derived from stem cells and specific organs can be used for their
molecular impact on organogenesis study. Here we discuss different areas of biological
science research that organoids have applications in. (Fig. 3).
Organoid developed for tissue modeling
Organoids hold an advantage over traditional techniques to solve unanswered questions
in developmental biology because of the accessibility of model systems, especially for
human models. For example, the unique division mode of neural stem cells has been
studied using human brain organoids [105, 117, 151]. Similarly, the differences in tissue
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morphogenesis and timing between humans and rodents have been studied using
retinal organoids. Furthermore, organoids may be used to study processes that differ in
model organisms and humans, such as GI tract development, and to model adult
homeostasis. Specifically, the role played by the crypt niche in self-renewal and
differentiation of stem cells has been studied using intestinal organoids. Regenerative
events in adult organs, such as liver and stomach, have also been closely recapitulated
by organoids derived from adult progenitors.
Organoids developed for regenerative medicine
Organoids also provide an alternative for cell and whole organ transplantation by
providing autologous tissue. Organ transplant procedures with high demands and low
success rates, such as renal transplants, may be improved using corresponding
organoids. Successful transplantation of kidney organoids in adult mice has been
already achieved by Taguchi et al., paving the way for a promising future for organoid
transplantation [109, 152]. Stem cell therapies are being aided by retinal organoids in
clinical trials to replace degenerating cell types. On similar lines, intestinal organoids are
also under investigation to treat damaged and diseased colon.
Organoids used for therapy response in cancer and other pathologies
The failure rate of traditional models of therapy testing translating to patient treatment
regimens has launched a hunt for more reliable and physiological models, such as
patient-derived organoids for drug screenings and drug discovery studies. Yin et al.
recently reported the use of primary intestinal organoids for modeling retroviral infection
and antiviral therapy in an attempt to address the lack of potent antiviral therapies [153].
In another study, Ogawa et al. used patient-derived cholangiocyte organoids to correct
the misfolded CFTR protein (cystic fibrosis transmembrane conductance regulator)
[154].Using a similar strategy, Schwank et al. used CRISPER/Cas9 to repair the function
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of CFTR in intestinal stem cell organoids. Such studies highlight the utility of organoids
in disease modeling and therapeutic testing [155].
Additionally, Huang et al., in a recent study generated pancreatic ductal
organoids and induced mutations in them to successfully model pancreatic ductal
adenocarcinoma. They then used these organoids to test the therapeutic efficacy of a
histone methyltransferase inhibitor, working along the idea of disease modeling and
therapy [156]. Skardal et al. established 3D liver organoids to model colorectal cancer
metastasis and were able to test therapies on metastatic disease [150]. Van de Wetering
et al. established tumor organoid cultures from 20 colorectal carcinoma patients
representing most genetic subtypes of colorectal cancer generating a living biobank
[157]. In these and other examples, we can see that organoid technology provides an
opportunity to bridge the gap between patient-derived cell lines and xenograft mouse
models, generating a link between cancer, genetic, and patient trials to make possible
better and personalized therapy designs. All these studies suggest that 3D organoids
models are still developing but have immense potential for modeling various diseases
and use in therapy design.

3A.8 Conclusions and Perspectives: Towards modeling accurate homeostasis and
disease

Organoid cultures are accessible and physiologically relevant models to study biology.
They can be derived from multiple sources, and they maintain stem cell or progenitor
population. [93, 103, 140, 144, 158]. These models are robust in recapitulating in vivo
tissue biology and have shown to be reliable in testing therapeutic response. They have
the capacity to serve as a platform for translational research and high throughput
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preclinical screenings. Organoid technology has worked successfully with current
research methodologies and found its niche.
More development will be seen in 3D organoid systems that will compensate for
the limitations the technology still suffers, however. Despite this, we hope to see the
extensive use of organoids in many more avenues. Patient-derived organoids provide an
opportunity to develop personalized treatment regimens for patients since biopsies can
be an excellent source of disease site tissues and normal tissues for deep sequencing.
This would, in turn, reveal causal mutations and phenotypic profile to generate
therapeutic approaches tailored to each patient. Once organoids from patients are
generated, they can be used to test efficacy or resistance to proposed regimens.
Additionally, organoids generated from healthy tissues can be used to weed out toxicity
and other undesired effects of the proposed therapy.
Organoid studies are being used for disease modeling for developmental
disorders, cancer, degeneration, and other infectious diseases [142, 144, 150, 153, 155,
159-162]. This may also be achieved by introducing patient mutations in human PSCs,
using genome-editing techniques, by generating organoids or inserting mutations directly
into organoids. Organoids are also being employed for screening drugs, testing for
efficacy and toxicity by modeling different degenerative conditions such as liver fibrosis
or cystic kidney diseases where effective treatment regimens are required. If successful,
this approach could lead to a reduction of the use of animal testing, which would be
reserved only for studies requiring whole-organism readouts.
Organoids have found their place in everyday research and to date have
significantly supplemented our knowledge and ability to model diseases. We have seen
an exponential increase in their usage and application since the first introduction. Their
reliability, robustness, and amenability for research have yielded enormous downstream
applications, highlighting their role in recapitulating homeostasis and diseases. These
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characteristics make organoids extremely exciting and promising technology that holds a
promising future for therapeutics.
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3A.9 Figures and legends

Fig. 3.1 Representation of the organoids generated, and the media compositions
required: These hosts of organoids have been generated from different source
materials, including iPSCs, adult stem cells, embryonic tissues or cells and adult tissue
explants. Different media compositions are required for each type of source material
used and the type of differentiation to be achieved (organ-specific), which is elaborated
in detail in the text. Specifically, cerebral organoids need a stepwise incubation of
pluripotent stem cells in neural induction media (DMEM-F12, N2 supplement, GlutaMAX
supplement, MEM-NEAA, heparin) followed by cerebral induction media (DMEM-F12,
Neurobasal medium, N2 supplement, insulin, GlutaMAX supplement, MEM-NEAA,
penicillin-streptomycin, 2-mercaptoethanol, B27 supplement). Mammary organoids can
be developed from tissue fragments using media composed of DMEM/F12, FBS, ITS
Selenite media supplement, FGF2, FGF10 for mouse or EpiCult B medium
supplemented with hydrocortisone, insulin, FGF10, HGF for humans. Liver organoids
can be generated by mixing tissue fragments in DMEM/F12 media supplemented with
FBS, EGF, RSPO1, FGF, HGF, Nicotinamide, and insulin. Pancreatic organoids need
a media comprising of DMEM/F12, B27 supplement, Nicotinamide, Noggin, EGF, FGF,
and RSPO1. Ovarian organoids are generated by seeding fallopian epithelial cells in
Matrigel with media comprising AdDMEM/F12, Wnt3A, RSPO1, HEPES, GlutaMAX,
B27, N2 Supplement, EGF, noggin, FGF10, Nicotinamide, Y-27632, and SB431542.
Prostate organoids need a media containing DMEM/F12, B27 Supplement, Nacetylcysteine, EGF, Noggin, RSPO1, A83-01, and DHT. Kidney organoids need a
media containing DMEM high glucose, FBS, NEAA, GlutaMAX, Heparin, APEL media,
FGF9, SB431542, and CHIR99021. Gut or intestinal organoids need a media
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composition of DMEM/F12, FBS, B27, EGF, RSPO1, Noggin and Wnt. Specific
cultivation of stomach organoids needs media composition same as intestinal organoids
with the addition of FGF. Lung organoids can be generated and grown in media
containing DMEM/F12, FBS, B27, N2 Supplement, GlutaMAX, FGF4, Noggin,
SB431542 and CHIR99021.
Abbreviation used are: Y-27632:ROCK inhibitor, SB431542:TGF-β R Kinase Inhibitor IV,
ITS: Insulin Transferrin-Sodium, NEAA: Non Essential Amino Acid Culture Supplement,
EGF: Epidermal Growth Factor, RSPO1: R-spondin-1, Wnt3A: Wingless-Type MMTV
Integration Site Family Member 3A, T3: Triiodothyronine, FBS: Fetal Bovine Serum,
FGF: Fibroblast Growth Factor, HGF: Hepatocyte Growth factor, DMEM/F12: Dulbecco's
Modified Eagle Medium: Nutrient Mixture F-12 , DHT: Dihydrotestosterone , CHIR99021:
glycogen synthase kinase 3 inhibitor.
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Fig. 3.1
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Fig. 3.2 General scheme of generating organoids and representative figures of
organoids generated by our laboratory:
The flowchart represents the scheme of organoid isolation which is modified for each
organoid according to the organ or tissue architecture to generate submerged organoids.
Briefly, desired source tissue (progenitor cells or tissue fragments) is isolated from the
host by mincing the organ and then subjecting it to enzymatic digestion. The digestion
media composition and the digestion protocol are decided depending on the host tissue.
The digestion media usually contains a mixture or Dispase and Collagenase or
Collagenase alone and can take from 30 mins to 4-6 hours. Following digestion, the cells
are mixed in the matrix (like Matrigel or collagen) suitable for the desired organoids. A
suitable media is overlaid once the matrix solidifies. Once generated, organoids grow in
ductal like morphologies like their human counterparts. Picture panels depict the
microscopic pictures of organoids generated in our lab from normal and cancerous
prostate and pancreas as well as lung cancer organoids (upper panel) along with
hematoxylin and eosin stained sections of the same (lower panel) depicting the
difference in the organization of cells in each of these organoids. Figure magnifications
are mentioned in each of the figures.
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Fig. 3.2
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Fig.3. 3 Potential applications of organoids generated:
The figure presents prospective applications of organoid culture tool for the
advancement of biological research. The arrows in the figure represent the flow of
information from tumor modeling, disease modeling and developmental biology studies
towards therapeutic interventions. To expand since organoids, represent tissue
homeostasis in vitro, they can be used to model pathologies by inducing desired
mutations or exposing them to necessary stimulus or pathogens. Following which the
pathogenesis and disease development can be studied. Such studies facilitate further
research to study drug response or generate organoids directly from patients to device
personalized therapeutic strategy as represented by the arrows emerging from disease
modeling bubble. Similarly, modeling cancer initiation and progression in organoids can
facilitate therapeutic response studies and the discovery of new oncogenic proteins or
antigens that can be targeted illustrated by arrows emerging from the Tumor modeling
bubble. Additionally, lineage tracing studies or organ development studies using
organoids have immense potential for the field of organ replacement therapy and can
help neoantigen discovery for cancer research (arrows emerging from developmental
biology studies bubble). The dashed arrows represent the overlapping domains amongst
these applications as explained above.
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Fig. 3.3
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3B Generation and optimization of organoid cultures

3B.1 Background and rationale

3D culture or organoid cultures provide a robust experimental model that simulates in
vivo biology and pathologies and are becoming the popular choice of model to study
therapy response (Kaushik et al. 2018). These are cell-derived models that simulate
endogenous

cell

organization

and

architecture

hence

enable

cell

behavior,

pathobiological and drug response research. Organoids can be generated from very little
source material like biopsies, circulating cells isolated from patients granting an
opportunity for developing personalized therapy. Further their potential applications in
the fields of disease modeling, gene editing, organogenesis, and transplantations makes
them instrumental research tools. For these reasons, many studies have attempted to
setup cryopreserved biobanks of human organoids as a resource for researchers and
clinicians.
In 2009 Sato et al. demonstrated that embedding LGR5+ intestinal stem cells
into a 3D matrix yield self-organizing organotypic structures revealing a single adult
stem cell has the potential to generate organoids [163]. R-spondin1, EGF and noggin
were shown to be critical to mimic the in vivo stem cell niche vital for an organoid
generation

in

this

study.

Further

may studies

utilized similar

niche factor

supplementation to create organoids for other multiple mice and human epithelia,
including colon, liver, pancreas, prostate, stomach, fallopian tube, taste buds, salivary
glands, esophagus, lung, endometrium, and breast [92]. Many studies since have
reported stable long-term expansion and cryopreservation of organoids; this makes
organoids attractive tools considering lack of available source tissue is a hindrance in
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cancer research. Organoids can also be genetically modified and remain genetically
and phenotypically stable allowing for a wide range of applications in cancer research.
Huch et al. published the first study reporting conditions for in-vitro expansion
of adult bipotent pancreatic progenitor cells through Lgr5/R-spondin axis [164]. A
crucial component of their culture medium is the Wnt agonist RSPO1, the recently
reported ligand of Lgr5 and its homologs. Wnt signaling is vital for pancreatic
development during embryogenesis but is inactive in adult pancreas [165-167]. An
injury to adult pancreas results in reactivation formation of new pancreatic islets in a
similar fashion as embryonic pancreas where multipotent progenitor cells give rise to all
pancreatic lineages (acinar, duct and endocrine) [168-170]. Partial duct ligation (PDL) or
acinar ablation studies have shown that duct cells can proliferate and differentiate
towards acinar, duct and endocrine lineages, suggesting presence of pancreatic
progenitor pool within ductal cells in adult pancreas [139, 171-175]. Wnt-Lgr5-Rspo
signaling axis can be exploited to create culture conditions that enable long-term
expansion of adult pancreatic duct cells, with the ability to differentiate towards both duct
and endocrine lineages in the presence of proper signals [164].
3D organoids have also been developed from malignant mouse and human
pancreatic tissues and utilized to investigate PDAC pathogenesis [93, 137, 176].
Organoids derived from wildtype and genetically modified mouse models PDAC
recapitulate

disease

progression

with

close physiological relevance in vitro.

Additionally, organoids derived from mouse and human PDAC tissues generate PanIN
like lesions and progress to invasive PDA, following transplantation. Whereas, organoids
from wild-type mouse normal pancreas regenerate normal ductal architecture [137].KC
(Kras; PdxCre) and KPC(Kras; p53; PdxCre) mouse models are well established
genetically engineered autochthonous mouse models of PDAC and have been used to
generate murine PDAC organoids to study therapeutic response [137, 177].
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Several studies have reported the development of organoids from stem cells that
retain progenitor cells in different organs [102, 163, 164, 178]. Murine pancreatic
progenitors grow into 3D complex organoidal structures that spontaneously undergo
pancreatic morphogenesis and differentiation when embedded in Matrigel and presence
of appropriate medium composition [179]. Recapitulation of in vivo niche signaling
interactions is necessary to enable expansion of progenitors, which is achieved by active
Notch and FGF signaling [179]. Single isolated adult mouse pancreatic progenitors
which belong to ductal lineage have the potential to expand and form organoids in
Matrigel-based 3-D culture system [102, 179]. Pancreatic organoids maintain Lgr5
expressing population and can differentiate to endocrine cells [102]. Human and mouse
pancreatic

organoids

allow

expansion and the generation of progenitor cell

subpopulation. high aldehyde dehydrogenase activity (ALDHhi) and expression of
pancreatic progenitor markers (PDX1, PTF1A, CPA1, and MYC) are maintained in
pancreatic organoids [102, 164].
PDAC organoids have been used to study therapy response [159, 180]. Human
patient-derived

PDAC

organoids

carry

patient

specific

and

histopathologic

characteristics and can be used to study the etiology of patient tumor and therapy
response. Genetic and structural features of primary pancreatic adenocarcinoma tumors
are well represented by human PDAC organoids [181].
We decided to generate 3D culture/organoids from mouse models of pancreatic
cancer to study therapeutic strategies and PDAC pathology. We utilized tumors resected
from KC and KPC mouse models and wild type mice to generate our organoids. We
standardized our protocol and culture conditions by building on previously established
culture conditions reported in Sato et. al. We also created organoids from adjacent
normal and tumor tissues obtained from PDAC patients to test the effect of our therapy
in clinical samples.
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Apart from establishing Pancreatic organoids we also developed lung and
prostrate organoids in our lab for further utilization in metastatic as well as other studies.
In this part of my thesis, we report the generation or organoids and optimization of
experimental protocols for normal and tumor organoids. We also report the maintenance
of cancer stem cells in our organoids and standardize a method to track and analyze
organoid growth and therapeutic response. We use these standardized protocols and
methodologies in the next part of this thesis to evaluate our proposed therapy.
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3B.2. Results
3B.2.1 Generation of Organoids
3B.2.1a. Murine Pancreatic Organoids

Pancreas or pancreatic tumors were resected from wildtype C57BL/6, KC, and KPC
mice. The resected tissue was mechanically minced to a size of approximately one
millimeter. Minced tissue was digested with a mixture of collagenase XI and dispase in
DMEM media with the addition of 1% FBS for KPC organoids. A period of 30 minutes to
one hour was enough for digestion of wild-type pancreas whereas KC and KPC
organoids required 1 hour to 3 hours to digest. During the period of digestion at 30minute intervals, an aliquot of supernatant from digesting tissue was observed under a
microscope. After one and a half hour chains of cells could be observed in the
supernatant under the microscope. These chains represent ductal cell population. The
supernatant from this digest was taken for organoid culture, and the remaining digest
was incubated again for further digestion. The supernatant was taken at several time
points until we stopped seeing strings of ductal cells under a microscope. The
supernatant was then washed and embedded in growth factor reduced matrigel and
seeded in 48 well plates.The seeded matrigel domes were allowed to set for 15 minutes
in the incubator.
KC

Organoids

were

supplied

with

complete

AdDMEM/F12

medium

supplemented with HEPES, Glutamax, penicillin/streptomycin, B27, N-acetyl-L-cysteine,
epidermal growth factor (EGF). Although organoids formed in this media, we got a very
low efficiency. Additional growth factor was added for an enhance efficiency namely,
fibroblast growth factor 10 (FGF10), Nicotinamide, and A83-01 (TGFb inhibitor), Noggin,
R-spondin. However, KPC and normal organoids needed supplementation with FBS for
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initial establishment. A recent study reported tumor organoids to appear spherical under
a microscope, whereas normal pancreatic organoids appear cystic (Seino et al. 2018).
Once developed, our tumor organoids grew as single-cell-layered spherical ductal
structures in vitro and developed more complex structures as the days progressed. Our
normal organoids had the cystic appearance and did not gather morphological
complexity in a culture like that of HC, KPC organoids (Fig.3.4a).

3.B.2.1b Human pancreatic organoids

Lack of available human patient tissues is a major hindrance to pancreatic cancer
research. Human PDAC organoids have potential in providing ample research material
for drug screening and a window for personalized therapy protocol development specific
to the patients. Human tumor and adjacent normal samples were obtained from the
surgery department and subjected to mechanical and digestion similar to murine
organoids with addition of Primocin and A83-01 in digestion media. The digestion and
seeding protocol was similar to murine organoids. Human PDAC and normal like
organoids needed a further enriched media with the addition of Primocin, gastrin in
complete media for both tumor and normal and PGE2 in normal organoids. One
representative figure from the 4 successfully generated lines of patient PDAC organoids
has been provided in Fig. 2.1b. We could also generate organoids from MUC4 knockout
mouse model for PDAC developed in our lab (Fig.2.4C)

3.B.2.1c Lung organoids

Lung organoids have typically been derived from isolated progenitor cells from
dissociated lung tissue (Hogan et al. 2014). Basal cells exist in the pseudostratified
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mucociliary epithelium that lines mist of the conducting airways in the lungs and expands
to regenerate the lungs upon injury in adult mouse (Pardo-Saganta et al. 2015).
Organoids that represent the mucociliary epithelium of the lungs are generated by
seeding isolated basal cells in a matrigel based system (Roch et al. 2011; Tata et al.
2013). Isolated humans pluripotent stem cells (). Bronchioalveolar stem cells (BACs) are
club cells that exist in distal bronchioles and have the potential to differentiate into both
type 2 Alveolar cells (Stem cells) and airway cells. Organoids that contain both alveolar
cell and airway cell lineages can be derived from isolated BACs (). Both the processes
have strong requirement of EGF signaling to enable growth. The process of stable
human lung organoid development requires stepwise differentiation of pluripotent stem
cells from a definitive endoderm state to anterior foregut endoderm and finally to NKX2.1
expressing lung progenitors(). Activation of the hedgehog pathway followed by exposure
to FGF 10 signaling allows differentiation to an anterior foregut endoderm state, and
further exposure to differentiating factors like BMP signaling allows differentiation into
lung progenitors. To generate organoids from a mixed population of cells and to get
organoids that represent both proximal and distal epithelium we adapted from the
method developed by Biana et al. Lungs from C57BL/6 wildtype and KA (Kras G12D ;
AdCre) and KPA(Kras G12D ; p53R172H+ AdCre) were resected and subjected to mechanical
and enzymatic digestion similar to pancreatic tissue as reported before. 30 minutes of
digestion was enough to allow digestion sufficient for an organoid generation (large
clumps of cells were not visible in the supernatant from digesting mixture). The
supernatant was then seeded in low attachment plates in presence of BMP, TGFb and
Wnt activators, FGF and RA activators allowing expansion of stem cell and progenitor
populations. This lead to formation of lung spheroidal structures which were them
embedded in Matrigel. Once matrigel solidified the media was replaced to Wnt, FGF,
cAMP and glucocorticoids containing media to enable growth of lung organoids. We
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successfully generated lung organoids representing two different cancer grades (KA and
KPA) (Fig. 2.4D)
3.B.2.1d Prostate organoids

Development, homeostasis of prostate and prostate cancer all require active AR
signaling (Pienta KJ et al. 2008). Cell line cultures used for prostate cancer study do not
have an intact AR signaling pathway. Prostate organoids can be generated by isolated
luminal cells, which represent one of the progenitor populations in the prostate (Chua CV
et al. 2014). Prostate organoids derived from digested prostate tissues contain
multipotent progenitor cells from both luminal and basal lineages and active AR signaling
(Drost et al. 2016). Stable AR-responsive and progenitor pool containing prostate
organoid expansion require EGF, Noggin, and R-spondin signaling along with AR
signaling (Drost et al. 2016). We adapted previously published protocols for prostate,
pancreas and intestinal organoids and developed murine wildtype prostate and prostate
cancer organoids. Prostate and prostate tumor tissues from wildtype C57BL/6 and Pten
conditional knockout mouse was carefully resected avoiding seminal vesicles, remaining
urogenital system and fat tissue. The resected prostate was minced into small pieces of
around one millimeter followed by enzymatic digestion with Collagenase type II. After 2
hours of digestion supernatant from the digest was mixed with Matrigel and seeded as
domes in 48 well plates. Once the matrigel solidified prostate organoid media comprising
DMEM/F12, B27, N-acetylcysteine, EGF, Noggin, R-spondin 1, A83-01 and DHT was
added to the matrigel domes. We successfully generated organoids from normal
prostate and prostate cancer (Fig. 2.4E).
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3B.2.2 Maintenance of progenitor cells or CSC pool in pancreatic cancer
organoids.
Organoids were stained for expression of several self-renewal and CSC markers to
examine retention and expansion of CSC population in developed PDAC organoids.
Common CSC and stem cell markers utilized in pancreatic cancer were used including
OCT4, SOX2, CD44v6, ALDH1, ABCG2, CD133, ESA, and pEGFR to include multiple
CSC subpopulation. The beautifully stained organoids confirmed the presence of CSC
and self-renewal markers (Fig. 2.5). A recent publication revealed the presence of a new
CSC population in PDAC called autofluorescent cells. These cells retain auto fluorescing
riboflavin in their ABCG2 expressing vesicles and hence exhibit autofluorescence. We
could observe the presence of this newly identified subset of CSC; autofluorescent cells
in established organoids (Fig.2.5).

3B.2.3 Tracking Growth and therapy response in organoids
We used KC organoids for standardization of the protocols. We could track individual
organoids over a span of several days to analyze the change in the size of the organoids
over time (Fig. 2.6 a). Our studies revealed that KPC organoids grow significantly faster
in culture compared to KC organoids (Fig. 2.6 b). This is an expected growth pattern
since KPC mice develop more aggressive tumors as compared to KC mouse. This
growth pattern also suggests that organoids retain their in vivo growth pattern in vitro.
We could also perform drug treatment and follow organoids to analyze the change in
organoids size due to therapy representing growth inhibition (Fig.2.7a,b,c). We use this
method of growth analysis in later studies for therapy response analysis.
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3B.3 Discussion
Developmental pathways employed in embryonic development of pancreas are
evolutionarily conserved [93, 137, 163, 182, 183]. Signaling pathways such as Wnt,
BMP, FGF, HGF, EGF, RA and TGFb are some of the vital pathways responsible for
generating a morphological gradient that allows development of the pancreas. The
standard requirement to enable the growth of pancreatic 3D cultures is to supply factors
to enable the functionality of these pathways since they promote proliferation, survival,
and migration of progenitor pools [92]. To provide a supportive ECM which also allow
cell motility we used matrigel as reported by several other studies. To supply necessary
nourishment, we try multiple media compositions with limiting growth factor availability
and find a difference in efficiency of organoids generation. This suggests a requirement
of an enriched media for high-efficiency organoids generation but the possibility of
utilizing a growth factor limiting media to facilitate the growth of organoids as per the
need of the experiment. A recent study has reported limiting the availability of EGF and
Noggin to allow enrichment of KRAS mutant and SMAD 4 mutant organoids [184].
Previous studies from other labs have reported the development of pancreatic tumor
organoids that retain attributes of pancreatic ductal adenocarcinoma from duct cells
isolated from neoplastic tissues [137]. We mince and enzymatically digest pancreatic
tissues enough to isolate chains of ductal cells.
Different enzymes and duration of digestion were required for tissues from
different origins such as the normal murine or human pancreas, and KC, KPC, and
patient pancreatic tumors. It is critical to achieving appropriate digestion of the tissue
since too much or too little digestion would both lead to failure of the protocol. Overdigestion damages the ductal cells whereas under digestion leaves them in clumps that
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have cells from acinar and ductal cells and presence of acinar cells limits ductal cell
growth.

3B.4 Figures and Legends

Fig. 3.4 Established KC, KPC ad Human PDAC organoids
Organoids were generated from respective murine or human tissues following enzymatic
digestion and matrigel embedding. After a week in culture murine organoids were
observed under microscope and images were clicked. Human organoids were cultures
for 3 weeks before the pictures were clicked. Organoids were subsequently paraffin
embedded and sectioned. The slides were then stained with hematoxylin and eosin to
observe structural morphology of the organoids. A) Microscopic and Hand E stained
representative images of established mouse KC, KPC and wildtype organoids. B)
Microscopic and Hand E stained representative images of established human PDAC
organoids. C)Microscopic and Hand E stained representative images of established
MUC16 Ko KPC organoids. D) Microscopic and Hand E stained representative images
of Prostate Normal and Cancer organoids. E) Microscopic and Hand E stained
representative images of established Lung Cancer Organoids
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Fig. 3.4
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Fig. 3.5 CSC population is maintained in pancreatic cancer organoids
Organoids were paraffin embedded and sectioned. The slides were then stained with
respective fluorescently stained antibodies and DAPI to observe molecular expression.
A) Immunofluorescent stained images of pancreatic organoids stained for CSC and selfrenewal markers CD44, ALDH1, ABCG2, CD133, OCT4, SOX2, ESA and pEGFR. This
suggests presence of multiple cancer stem cell subpopulations in our organoids
including but not limited to CD133 expressing, ALDH1 expressing and CD44 expressing
populations that have widely studied in PDAC. B) DAPI stained organoids with
autofluorescent cells. Organoids were paraffin embedded and sectioned. The slides
were then DAPI stained to observed presence of any autofluorescent cells.
Autofluorescent cells represent retention and expansion of another recently identifies
cancer stem cell subpopulation in pancreatic cancer.
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Fig. 3.5
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Fig. 3.6 Organoids growth in culture
KC and KPC organoids were embedded in matrigel domes and seeded in 48 well plates
After a two days in culture ten KC and KPC organoids were observed under microscope
and images were clicked from multiple fields. The wells containing these organoids were
then marked for the location of these organoids. For the next five days the location and
size of these organoids were tracked/followed. At the end of five days pictures were
clicked again for the tracked organoids. A) Microscopic image of KC and KPC pancreatic
organoids that have been tracked over 5 days representing change in their size B)
Quantification of change in the size of organoids from day 0 to day 5 to examine their
growth in culture. The sizes of tracked organoids were measured by clicking their picture
and measuring each organoid using the Moticon Software. Size change of the organoids
from day 0 to day 5 was then calculated. KPC organoids grew at a higher rate in culture
compared to KC organoids revealing their aggressiveness (P<0.005).
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Fig. 3.6
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Fig. 3.7 Growth inhibition tracking in organoids
KPC organoids were embedded in matrigel domes and seeded in 48 well plates in two
groups “control” and “Afatinib” (A small molecule pan-EGFR inhibitor approved from
NSCLC). After two days in culture both groups of organoids were observed under
microscope and images were clicked. The wells containing these organoids were then
marked for the location of these organoids. Afatinib was added at a concentration of
0.1µM in group named “Afatinib” and control group was given equal microliters of PBS.
For the next five days the location and size of these organoids were tracked/followed.
Media was changed on day 2 and 4 for both groups with re-administration of Afatinib and
PBS. At the end of five days pictures were clicked again for the tracked organoids . A)
Microscopic image of pancreatic organoids for day 0 and day 5 in the two groups
(Untreated “control”, Drug-Treated” Afatinib”). B) Quantification of change in the size of
ten organoids in control and drug-treated group from day 0 to day 5. The sizes of tracked
organoids were measured by clicking their picture and measuring each organoid using
the Moticon Software. The average size in the group is written in red over each bar.
Evaluation of % size change in organoids upon drug treatment to evaluate therapy
response. Therapy response was evaluated by comparing change in organoids over 5
days in the two groups. Control organoids showed in average 7% increase in their size
(area). Drug-treated organoids decreased in size by 56% suggesting successful
inhibition or growth due to therapy(P<0.5).
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Fig. 3.7
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CHAPTER 4: PANCREATIC CANCER STEM CELL TARGETING: AFATINIB
INHIBITS EGFR/FOXA2/SOX9 AND DECREASE STEMNESS PROPERTY
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4.1 Introduction
Improving disease-free survival and a patient’s quality of life is the comprehensive goal
of research against PC. Although several therapies have been tried, none has
significantly improved patient outcomes. The present therapeutic options for advanced
metastatic PC primarily include gemcitabine and its combination with erlotinib or nabpaclitaxel or FOLFIRINOX [7]. Despite all the available therapies and surgical
interventions, the average five-year survival rate for PDAC patients is merely 8% [7]. The
primary cause of PC mortality is metastasis. Approximately 53% of patients upon
diagnosis present with an advanced metastatic stage of the disease [7]. Furthermore,
emerging evidence suggests that PC is metastatic even at its conception, which makes
targeting this aggressive metastatic cancer a challenging task [5]. One of the major
factors contributing to metastasis is mobilization of CSCs [185, 186] a small
subpopulation of cells in the tumor also referred to as side population (SP) which has
been shown to be vital for PC metastasis and drug-resistance [2, 187]. These cells are
also responsible for drug resistance and disease relapse in PC and other types of
cancers [2]. Conventional chemotherapeutic drugs act on differentiated tumor cells but
fail to target the CSC population. It is now clear that the success of new PC therapies in
achieving durable remissions will depend on targeting CSCs; therefore, understanding
mechanisms for targeting PCSCs is critical.
The EGFR family of proteins are involved in the initiation and progression of PC, with
EGFR mutations being essential for the initiation process [188]. Many ongoing clinical
trials are using inhibitors against EGFR family of proteins for therapy against cancers.
The USFDA recently approved one such inhibitor erlotinib in combination with
gemcitabine for the treatment of advanced PC; however, later this treatment caused
dose-limiting toxicity and failed to control the compensatory changes in the
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phosphorylation of HER3, resulting in resistance against erlotinib [189, 190]. Afatinib is a
third-generation EGFR family inhibitor and has been shown to be superior in inhibiting
PC cell lines when compared to erlotinib [190]. It is an FDA-approved drug for non-small
cell lung carcinoma and is being investigated for several other cancers [191, 192].It is a
pan-EGFR inhibitor (targeting all EGFR family proteins) and is presently being
investigated as a single agent and in combination with other chemotherapeutic drugs in
49 clinical trials; however, few studies have examined its effects on CSC populations in
different cancers [193]. Our previous study has shown that afatinib can be used to inhibit
EGFR proteins in vitro and reduce colony formation and invasion of PDAC cell lines
[194].
Here we tested the potential of afatinib in specific targeting of the PCSCs along with
differentiated

cancer

cells.

We

identified

that

afatinib

inhibits

a

novel

EGFR/ERK/FOXA2/SOX9 axis and abrogates PCSC. Through inhibition of PCSC the
combination therapy of afatinib with gemcitabine inhibits PC as well as its metastasis.
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4.2 Results

4.2.1 High self-renewal marker expression in Gemcitabine treated and high-grade
pancreatic cancer.
The present standard of care for pancreatic cancer patients is either neoadjuvant
chemotherapy or chemotherapy depending on the spread and grade of the disease.
Cancer stem cells have been shown to remain intact even upon standard
chemotherapeutic treatments in pancreatic cancer [195]. Additionally, some recent
studies have suggested CSC enrichment due to chemotherapeutic drugs [196, 197].
With an objective to examine the presence of CSC population in PDAC patients, we
immunofluorescent stained PDAC tissue microarray for the presence of CSC and selfrenewal markers like SOX9, CD44, ESA and CD133 (Fig. 4.1A). We observed enhanced
expression of these markers in PDAC tissues compared to normal pancreatic tissue.
Upon segregating tissue samples according to patient grade, we found an increase in
these markers as the grade and severity of PDAC increases (Fig. 4.1A,B). There was a
significant increase in expression of these markers from normal pancreatic tissue to
PDAC stage II grade 2 malignant tissue and finally to PDAC stage III grade 3 malignant
tumors. Amongst these markers, SOX9 is known to be a master regulator for several
stem cell genes in the pancreas as well as a valuable marker for the ductal lineage of
pancreatic cancer cells [198, 199]. To examine how chemotherapeutic treatments, affect
PCSCs we immunohistochemically stained human PDAC tissue microarray for SOX9
expression. The stained slides were scored with the help of a pathologist. A subset of
PDAC tumors with a history of chemotherapeutic treatment were found to express a
significantly higher amount of SOX9 compared to patient samples with no history of
chemotherapy (Fig. 4.1 C). Although when the collective of all samples were compared
the difference in SOX9 expression was not significant which can be attributed to
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extensive intertumoral heterogeneity that exists in PDAC. High expression of CSC
markers in PDAC samples and patient samples with a history of chemotherapeutic
treatments suggests the role of PCSCs in disease aggressiveness and a probable
enrichment upon chemotherapy.

4.2.2. Development and characterization of murine PC organoids
Pancreatic tumor organoids developed from neoplastic pancreatic duct cells were
previously shown to retain the same attributes as the pancreatic ductal adenocarcinoma
(PDA) stage [137]. Therefore, to examine the treatment efficacy of afatinib and
gemcitabine on PC, we generated organoids from pancreatic tumor tissues of KC and
KPC mouse. (Fig. 4.2A). Once developed, they grew as single-cell-layered ductal
structures in vitro and developed more complex structures as the days progressed (Fig.
4.2B, Fig. 4.2C). 3-D tumor organoids were used since they are more physiologically
relevant than traditional monolayer cultures to test therapy response [93].
Afatinib and gemcitabine inhibit the growth of tumor organoids derived from KC, KPC
mice, and human PC tumors.
EGFR family of proteins are implicated in multiple cancers including PC [200]. In PC, the
presence of EGFR in serum has been shown to be correlated with poor prognosis [201],
and inhibition of EGFR via erlotinib has shown survival benefits for PC patients [202].
Once developed, KC and KPC organoids and human PC tumor (Supp. Fig. 1A and Fig.
1A, B and C) were treated with afatinib alone and in combination with gemcitabine.
Results showed that KC and KPC control organoids left untreated grew in size by 45%
and 60% respectively (Supp. Fig. 1B, C and Fig.4.2D, E,) which we attributed to their
normal growth. Upon afatinib treatment, KC and KPC organoids decreased in size by
25% and 16% (Supp. Fig. 1B. C and Fig. 4.2D, E); we also observed an increase in the
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size of KC and KPC organoids by over 50% on treatment with gemcitabine (Supp. Fig.
1C, D). Since the growth of these organoids has been linked to their ability to maintain
progenitor cells or stem cells [203], we presume that the increase in the size of the
organoids is due to enrichment of CSCs upon gemcitabine treatment. Our results
showed combination treatment with afatinib and gemcitabine decreased KC organoid
size by 57% (Supp. Fig. 1B, C), suggesting a potential synergistic effect of the
combination in inhibiting PDAC.
Interestingly, the concentration of afatinib (0.1 μm) employed in KC organoids was not
sufficient to restrict the growth of KPC organoids (Supp. Fig. 1F). We found that an
increased concentration of afatinib (0.5 μm) with gemcitabine (1 μm) inhibited KPC
organoid growth and size by over 50% in comparison to untreated control, which grew in
size and complexity. In both KC and KPC organoids, the untreated KPC control
organoids evolved from single-cell-layered ductal structures to more complex cribriform
structures, whereas afatinib restricted this growth (Fig. 4.2E, and Supp. Fig. 1C). The
combination also visibly eradicated complex organoid structures as revealed by H&Estained sections (Fig. 4.2E, and Supp. Fig. 1C), which suggests the therapy could
reduce the aggressiveness of PC. Over 40% of organoids remaining after seven days of
consecutive combination treatment in both KC and KPC organoids were broken, showed
no structural complexity or were eradicated or dead (Supp. Fig. 1D, E).
Further, we developed human pancreatic tumor organoids (Fig. 4.2C) to test the efficacy
of afatinib and gemcitabine and their combination. Treatment with afatinib significantly
reduced the size of human pancreatic tumor organoids compared to control, whereas
the gemcitabine-treated organoids did not show any significant variation in size (Fig.
4.2F, G). However, the combination of afatinib and gemcitabine treatment significantly
reduced pancreatic tumor organoids size (Fig. 4.2F, G). Overall, these results suggest
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that afatinib alone and in combination with gemcitabine can decrease tumorigenesis and
growth in PC.

4.2.3. Combination of afatinib and gemcitabine significantly inhibits PC cell
growth and in vivo primary tumor and metastasis
To further determine the effects of afatinib and gemcitabine combination treatment on
PC cell lines, SW1990 and Capan1 cells were treated with different concentrations of
afatinib and gemcitabine for 24 h, and the IC50 value was calculated using MTT analysis
(Supp. Fig. 2A). To evaluate the inhibitory effect of afatinib and gemcitabine on the
EGFR family of proteins, SW1990 and Capan1 cells were treated with afatinib and
gemcitabine alone and in combination for 48 h. We found that treatment with afatinib
alone

and

in

combination

with

gemcitabine

effectively

downregulated

the

phosphorylation of EGFR, Her2, and Her3, with no change to their total protein
expression (Fig. 4.3A). However, treatment with gemcitabine alone leads to increased
phosphorylation of EGFR family proteins when compared to afatinib treatments.
Furthermore, we tested the combination therapy in vivo in xenograft nude mouse model
of PC. For this, athymic nude mice were orthotopically injected with luciferase-labeled
Capan1 cells into the head of the pancreas, and then divided into four groups (7 mice
per group): control (PBS), afatinib (orally), gemcitabine (intraperitoneal) and the
combination of both (Fig. 4.3B.) Afatinib treatment reduced the primary tumor burden by
over 1.8-fold (Fig. 4.3C, D) and reduced the number of metastasis spots per organ
(Supp. Fig. 2B); afatinib also decreased the metastatic incidence to the liver by 16-fold,
mesenteric lymph nodes and intestine by 8-fold and diaphragm and stomach by 4-fold
when compared to control (Fig. 4.3E, F). A combination of afatinib and gemcitabine
reduced the primary tumor by 2.4-fold compared to 1.5-fold by gemcitabine alone (Fig.
4.3C, D). The combination also decreased the incidences of metastases by 16-, 4-, 32-,
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8- and 4-fold in the liver, mesenteric lymph node, diaphragm, and stomach, respectively
(Fig. 4.3E, F). Taken together, these results suggest that afatinib treatment in
combination with gemcitabine can improve the anti-tumor effect of gemcitabine in PC.

4.2.4. Afatinib decreases the SP/CSC population and tumorsphere formation in PC
cells.
The decrease in tumor weight and metastasis in the xenograft mouse model encouraged
us to analyze the PCSC population because of its association with metastasis , poor
prognosis, and drug resistance in PC [204] . Hoechst-based FACS analysis was used to
analyze and isolate the CSC population as described in Materials and Methods (Fig.
4.4A). We next measured the drug sensitivity (IC50 values) of PCSC cells for
determining an effective drug dosage (Supp. Fig. 2A). SP cells were found to be more
sensitive to afatinib: 46.93% in Capan1 and 56.7% in SW1990 in comparison to their
parental populations. We also report that the SP fraction is more resistant to gemcitabine
(27.45% in Capan1 and 26.4% in SW1990 of parental populations) when compared to
their parental counterparts. Based on these results, we suggest that the SP fraction is
more sensitive to afatinib and resistant toward gemcitabine (Supp. Fig. 2A). To further
evaluate the effect of afatinib on CSC/SP populations, PC cells were subjected to
afatinib, gemcitabine and the combination treatment of both the drugs for 48 h and then
stained with Hoechst 33342 (a fluorescent DNA-binding dye) to analyze the CSC/SP
cells by FACS analysis [88, 205]. Afatinib and combination treatment significantly
decreased CSC/SP cells when compared to control cells; however, gemcitabine
treatment increased the proportion of CSC/SP cells (Fig. 4.4B, C, D, E). This result
suggests that afatinib is effectively inhibiting the CSC population while gemcitabine is
enriching it. To further validate the effect of afatinib on PCSCs, we performed
immunofluorescence analysis on SW1990 and Capan1 cells and found that treatment
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with afatinib inhibits the expression of CSC markers such as ESA, ALDH1, OCT4, and
SOX9 along with pEGFR (Supp. Fig. 3A and B) in PC cells. We also examined the effect
of afatinib on self-renewal and tumorigenic potential in CSCs using tumorsphere assay
on the isolated SP. Treatment with afatinib for 48 h significantly reduced the number of
tumor spheres (Fig. 4.4F, G), which further indicates that afatinib affects tumorigenic and
self-renewal properties of SP cells.

4.2.5. Treatment of afatinib significantly decreases the CSC markers in tumor
organoids and in pancreatic xenograft tumors
Our data demonstrated that afatinib acts on PCSCs and reduces their stemness and has
a pronounced anti-cancer effect when given in combination with gemcitabine. Therefore,
we next asked whether afatinib can downregulate the CSC markers in KPC organoids or
in the xenograft tumors. KPC tumor organoids were sectioned and immunostained for
CSC markers such as CD44v6, ALDH1, CD133, ABCG2, OCT4, SOX2, and ESA, along
with pEGFR. Confocal imaging of KPC organoids shows afatinib treatment drastically
reduced CD44v6, ALDH1, CD133, ABCG2, OCT4, SOX2, ESA and pEGFR, which were
further decreased by treatment with afatinib and gemcitabine combined compared to the
untreated control and gemcitabine-treated groups (Fig. 4.5 A, B and Supp. Fig. 4A). To
determine whether afatinib might also affect the CSC markers in vivo, we fluorescently
stained the pancreatic tumors resected from the xenograft experiment for CSC markers,
i.e., CD133, CD44v6 ESA and pEGFR (Fig. 4.5C, D). Afatinib treatment alone and in
combination with gemcitabine decreased CSC markers in primary tumors, suggesting
that afatinib is inhibiting PCSC stemness by downregulating CSC markers. Expression
of CD44v6 and CD133 has been shown to be critical drivers of PC metastasis [206-209],
and ESA is a well-known marker for PCSCs [210] Reduction in these markers further
demonstrates the efficacy of afatinib against PCSC. Interestingly, we also observed an
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increase in the same markers with gemcitabine treatment, which corroborated our
previous data suggesting gemcitabine enriches CSCs (Fig. 4.5 C, D). Since we saw a
decrease in primary tumor weight, we wanted to analyze the correlation of primary tumor
weight with metastatic incidence. Primary tumor weight correlated poorly with metastatic
incidence (Supp. Fig. 2C). These results suggest that a decrease in CSC markers by
afatinib may have led to a decrease in metastatic incidence.

4.2.6. Afatinib abrogates CSC markers and oncogenic signaling in CSCs
We next attempted to further explore the action of afatinib on self-renewal and CSC
markers in PCSCs. As expected, afatinib alone and in combination with gemcitabine
decreased self-renewal and CSC markers ALDH1, CD44, SOX2, SOX9, ESA, and
ABCG2 and inhibited activation of oncogenic proteins such as ERK and FAK (Fig. 4.6A).
To further validate our observation, we first isolated the SP and the NSP cells from
SW1990 as described above, and characterized their CSC markers; SP-SW1990
expressed higher amounts of SOX2, PAF1/PD2, ESA, ALDH1, SOX9, CD44v6, ESA
and SHH than its NSP counterparts (Fig. 4.6B). The SP-SW1990 cells were then
subjected to IC25 and IC50 concentrations of afatinib, which decreased expression of
CD44v6, ESA, SOX9 and ALDH1 along with pEGFR and pHer2 (Fig. 4.6C). Next, we
performed immunofluorescence analysis on the SP cells (isolated from SW1990 and
Capan1) and observed downregulation of ALDH1, ESA, SOX9 and OCT4 upon afatinib
treatment (Fig. 4.6 D, E, F, G). These results suggest that afatinib inhibits PCSC by
down-regulating molecules vital for CSC maintenance and self-renewal and hence
inhibiting stemness in CSCs.
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4.2.7. Afatinib decreases CSC populations via ERK/FOXA2/SOX9 signaling in
PCSCs.
To delineate the mechanism of action of afatinib, we performed a PCR array comparing
vital transcription factors and CSC markers in SW1990 cells (Fig. 4.7A). SW1990 cells
were treated with afatinib (IC50) for 4 days, followed by RNA isolation and PCR array
analysis. Afatinib treatment led to a greater than 2-fold decrease in 23 transcription
factors (ABCB5, ALCAM, BMP7, CD38, CD44, DACH1, DLL4, FOXA2, ITGA2, JAG1,
KLF4, MERTK, NOS2, PECAM1, PLAT, PLAUR, PTPRC, SNAI1, TAZ, TWIST2, ACTB,
B2M and HGDC) important for CSCs (Fig. 4.7A). These results were further validated by
qPCR and these genes were found to be downregulated upon four days of treatment
(Supp. Fig. 5C). We focused on FOXA2 because of its importance in promoting selfrenewal of pancreatic progenitor cells [211, 212]. FOXA2 is involved in regulation of
SOX9 expression, which is another self-renewal marker for PCSC[212]. We performed
qRTPCR analysis for FOXA2 and SOX9, which showed a decrease in mRNA levels
upon afatinib treatment on SP-SW1990 (Fig. 4.7B) suggesting a probable mechanism of
action. A scanning of the SOX9 promoter region for binding motifs for FOXA2 revealed
eight possible binding sites (Supp. Fig.5A) are the further corroborating possibility of
FOXA2 regulating SOX9. It has been reported previously that the phosphorylated form
of ERK regulates FOXA2 transcription, and hence we examined pERK levels. As
expected, afatinib treatment decreased pERK levels in PC cell line as well as in the
isolated SP/CSC population, suggesting that afatinib inhibits PCSCs by inhibiting
EGFR/ERK /FOXA2/SOX9 signaling (Fig. 4.7D, E).
To confirm this mechanism, we transiently knocked down EGFR (Fig. 4.7C) in isolated
SP/CSCs. Results showed that EGFR knockdown led to inhibition of pERK, SOX9 and
FOXA2 expression along with multiple other CSC markers such as OCT4, NANOG, and
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DCAMLK1 (Fig. 4.7C), confirming that the decrease in CSC markers and the
downstream signaling was due to EGFR inhibition. To further confirm the proposed
mechanism, we used two independent siRNAs to downregulate FOXA2 mRNA, which
led to a decrease in SOX9 expression, further corroborating the signaling axis
(pEGFR/pERK/FOXA2/SOX9) that is modulated by afatinib. To determine if afatinib
engages the same mechanism in organoids and xenograft tissues, KPC organoids and
xenograft sections were stained with pERK, FOXA2, and SOX9. The results showed that
afatinib decreased expression of these markers (Fig. 4.7G, Supp. Fig 4B, C, and Supp.
Fig. 5B, C, D). Altogether, our data provide a novel mechanism of action by which
afatinib inhibits the PCSCs in PC (Fig. 4.7H).
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4.3 Discussion
PC is a devastating disease with an abysmal prognosis [7, 213]. Current
treatment options that provide a survival advantage for advanced metastatic PDAC
include irinotecan liposome injection, gemcitabine, erlotinib, FOLFIRINOX, nabpaclitaxel, and combinations of these drugs. Such available therapies offer a 5-year
survival rate of merely 8% and an average overall survival benefit of 5.6 months to 11
months [214]. Aggressive and early metastasis is the chief cause of mortalities in PDAC,
and present evidence supports that PDAC may start disseminating as early as its
inception, accounting for the dismal prognosis [5, 193, 210, 215]. The cells that likely
initiate early metastasis are CSCs, which have the potential to seed tumors, promote
metastasis and provide drug resistance [193, 210, 215].Targeting CSCs may provide an
opportunity to impede tumor growth and metastasis in PDAC; however, currently used
therapies fail to inhibit these cells [7, 193, 216]. We report an increase in expression of
CSC markers in PDAC as the grade and severity of PDAC increases which is potentially
unaffected by chemotherapy. These results highlight the importance of developing
targeted therapy directed towards the CSC population in PDAC. Our study outlines a
strategy to effectively impede CSCs in PDAC by inhibiting their maintenance and
stemness properties.
As a strategy to target pancreatic CSCs, we tested combination therapy of panEGFR inhibitor, afatinib with first-line therapeutic drug gemcitabine. PDAC is known to
overexpress EGFR family members HER1 (40-70%) and HER2 (22%) [194], which are
vital for the self-renewal and maintenance of CSCs in PC [216]. Inhibition of EGFR
family proteins has been reported to downregulate tumor growth and metastasis in
multiple studies of PDAC. Furthermore, afatinib inhibits all four EGFR family members
by binding to their ATP binding domain and inactivating them [217]. Although afatinib is
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an FDA-approved drug for non-small cell lung carcinoma, emerging evidence suggests
its role as a potent inhibitor of multiple tumor types [190, 191, 217]. In this study, we
illustrated that inhibition of EGFR family of proteins using afatinib significantly reduced
the stemness properties of pancreatic CSCs and provided antitumor activity against PC
that was enhanced with gemcitabine treatment. Similarly, several other studies have
reported that EGFR family inhibition suppresses CSCs in brain, lung and breast cancers,
amongst others [218-220]. In addition, our study has shown that pan-EGFR inhibition
downregulates pancreatic tumor growth in xenograft mouse models.
To test the effect of afatinib in PDAC models, we developed 3-D tumor organoids
from KC and KPC autochthonous mouse tumors, which show clear progression
structures similar to PDAC progression. Emerging studies have substantiated the use of
tumor organoids for therapeutic response studies because of their high physiological
relevance [93] to the tumor. Tumor organoids recapitulate tumor architecture and biology
in vitro [137] and maintain a robust population of CSCs, making them ideal for our study.
Treatment with afatinib alone or with gemcitabine drastically inhibited the tumor size and
architecture in both models of tumor organoids as compared to gemcitabine alone,
demonstrating its effectiveness in impairing tumor growth. This was in concordance with
the reduction in tumor burden and metastatic incidence compared to gemcitabine alone
as observed in our xenograft mouse model experiments. These results also align with
our previous publication depicting a reduction in tumor burden upon inhibition of EGFR
family proteins by canertinib [194]. The observed increase in tumor organoid size and
structural complexity upon gemcitabine treatment, although not significant, may stem
from the enrichment of pancreatic CSCs, since CSCs are resistant to gemcitabine [215].
Interestingly, afatinib alone and in combination with gemcitabine decreased
distant metastatic spread suggesting afatinib could be effective in inhibiting the
metastasis in PDAC patients. This potential is supported by various other reports of
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metastasis being linked to the overexpression and amplification of EGFR and its other
family members HER2, HER3 and HER4 in several primary cancers like colorectal,
ovarian, non-small cell lung carcinoma and pancreatic cancer [221-224].CSCs are
known to be vital for metastasis in multiple cancers including PC. Thus, we decided to
analyze the effect of afatinib on the CSC population. Our data revealed that afatinib
significantly reduces the SP/CSC population in PDAC cell lines and inhibits their selfrenewal and tumorigenic potential. Furthermore, our immunofluorescence staining
results showed that afatinib treatment downregulated the expression of pEGFR and
CSC markers such as CD44v6, ALDH1, ESA, and CD133 in PC organoids and
xenograft tumor tissues.
In our study, we delineated a novel mechanism by which afatinib selectively
inhibits CSCs in PC. Afatinib treatment reduced several CSC markers along with
oncogenic signaling molecules like ERK and FAK. Additionally, we found afatinib
downregulated 22 vital transcription factors and CSC markers by more than two-fold
compared to control. Among them were several genes essential for PCSC maintenance
like KLF4, CD44, SNAIL1, TWIST2, FOXA2, and TAZ. FOXA2 caught our attention
because of its role in stem cell self-renewal [225]. It is also vital for lineage specification
in the pancreatic formation, and its expression is essential for pancreatic progenitor
cells. FOXA2 is also known to regulate SOX9 [212] Both SOX9 and FOXA2 were
downregulated by afatinib treatment, and availability of FOXA2 binding motifs in SOX9
proximal region suggested a probable mode of action. SOX9,is known to be vital for
CSC self-renewal and is a master regulator for several stem cell markers, is also
regulated by pERK [226] which is a downstream molecule of EGFR. This led us to
hypothesize that afatinib is targeting the EGFR/ERK/FOXA2/SOX9 axis to inhibit PCSCs
and their stemness properties. Our hypothesis was confirmed when knockdown of
EGFR decreased expression of FOXA2 and SOX9 and knockdown of FOXA2 decreased
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expression of SOX9. To further verify the mechanism of action, we stained afatinibtreated tissue and organoid sections with fluorescent antibodies against pERK, SOX9,
and FOXA2, and observed decreased expression of these stemness molecules. Overall,
these results affirm that afatinib inhibits CSC maintenance and proliferation via
EGFR/ERK/FOXA2/SOX9 inhibition in PC, thereby decreasing PC growth and
metastasis
In conclusion, afatinib treatment alone decreased the CSC/SP fraction in PC
models by altering their self-renewal/tumorigenic potential. Afatinib, unlike gemcitabine,
reduced tumor organoid size and architecture and inhibited CSC markers within these
organoids. Furthermore, combination therapy with afatinib and gemcitabine effectively
reduced tumor burden and metastatic incidence in a xenograft model of PC. Our
mechanistic studies indicate that afatinib acts on PCSC by inhibiting EGFR/ERK/FOXA2
to target SOX9. Altogether, we have shown that afatinib inhibits stemness properties in
pancreatic CSCs and in combination with gemcitabine may provide a potent therapy
against pancreatic CSCs; thus, this novel combination therapy may improve clinical
outcomes for PDAC patients.
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4.4. Figures and Legends
Fig.4.1. High self-renewal marker expression in Gemcitabine treated and highgrade pancreatic cancer.
A) Representative immunofluorescence image of Human tissue microarray with
pancreatic cancer and normal pancreatic cores stained with SOX9, CD44, ESA and
CD133, CSC and self-renewal markers (PDAC stage II grade 2 malignant, PDAC stage
III grade 3 malignant, normal pancreatic tissue). B) Quantitative analysis of CSC marker
expression in stained tissue microarray cores. Mean fluorescent intensities for Red,
Green and Blue stains was noted for each picture. Red and green staining was then
normalized by blue stain to get normalized mean fluorescent intensities. C)
Quantification of IHC scoring for expression of SOX9 in patient samples treated with
chemotherapy versus no chemotherapy depicting an increase in its expression upon
chemotherapeutic treatment. A human tissue microarray with information about the
primary

and

secondary

treatments

provided

to

the

patients

was

stained

immunohistochemically for expression of SOX9. The array was then scored for SOX9
staining with the help of a pathologist, for comparative analysis cores were divided into
two groups; Chemotherapy (the samples that had a history of chemotherapy with
gemcitabine of 5FU) and No Chemotherapy (the samples that had no history of
chemotherapy). A subset of 7 cores/samples treated with chemotherapy had significantly
high expression of SOX9 compared to average staining in no chemo group. These
sections were immunohistochemically scored for SOX9 expression.( P<0.05: *, P<0.001:
** P<0.0001: ***)
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Fig.4.2. Effects of afatinib on the development of pancreatic cancer (PC)
organoids.
A) Experimental scheme is showing the development of organoids and the treatment
strategy. B) Microscopic images of hematoxylin and eosin (H&E)-stained KPC mouse
PC organoids at days 2, 3 and 5. C) Microscopic images of H&E-stained human PC
organoids at days 2, 3 and 5.
Human PDAC organoids were embedded in matrigel domes and seeded in 48 well
plates in groups as per the scheme in “4.2A”. After two days in culture all four groups of
organoids were observed under microscope and images were clicked. The wells
containing these organoids were then marked for the location of these organoids. Drugs
were added at concentrations of 0.5µM Afatinib and 0.50.5µM Gemcitabine and control
group was given equal microliters of PBS. For the next five days the location and size of
these organoids were tracked/followed. Media was changed on day 2 and 4 for both
groups with re-administration of drugs and PBS. At the end of five days pictures were
clicked again for the tracked organoids. The sizes of tracked organoids were measured
by clicking their picture and measuring each organoid using the Moticon Software.
Therapy response was evaluated by comparing change in organoids over 5 days in the
groups. D) Quantitative analysis of the average size change in control and treated KPC
mouse organoid groups (Control, Afatinib, Gemcitabine, Afatinib, and Gemcitabine
combination treatments) over 5 days of treatment. E) Microscopic images of KPC PC
organoids before and after treatment for 5 days, and H&E-stained sections at the end of
the treatment. F) Quantitative analysis of the average size change in control and treated
human PC organoid groups (Afatinib, Gemcitabine, Afatinib, and Gemcitabine
combination treatments) over 5 days of treatment. G) Microscopic images of human PC
organoids before and after treatment for 5 days, and H&E-stained sections at the end of
the treatment.
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Fig. 4.3. Afatinib and gemcitabine combination treatment inhibits pancreatic tumor
growth and metastasis in an in vivo xenograft mouse model.
A) Effect of treatments (Afatinib, Gemcitabine alone and Afatinib with Gemcitabine
combination treatment) on the EGFR family of proteins in PC cell lines SW1990 and
CAPAN1. Cell lines were treated at IC50 concentrations. B) Study design for in vivo
mouse experiments. C) Statistical analysis of murine primary tumor weights upon study
completion. Upon euthanasia mice tumors were resected and weighed. D) Diffused
luminescent imaging tomography (DLIT) images of mice after 4 weeks of treatment
before resection. E) Metastasis incidence in mice after 4 weeks of treatment. Upon
euthanization internal organs of the mice were harvested and metastatic spots were
counted on the organs to calculate metastatic incidence F) Microscopic images of H&Estained sections of metastasis in vital organs of mice after 4 weeks of treatment.
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Fig.4.4. Afatinib inhibits cancer stem cell (CSC) counts and stemness.
A). Experimental design for experiments in the CSC population. B-C). PC cells were
seeded and treated with IC50 concentrations of Afatinib, Gemcitabine, a combination of
Afatinib and gemcitabine. Following 48 hours of treatment cells were subjected to FACS
analysis for side population to identify low Hoechst staining CSC population. Percentage
of side population (SP) cells in PC cell lines (B. SW1990 and C. Capan1) after 48 hours
of treatment. D-E). FACS analysis showing SP fraction in control and treatment groups
(Afatinib, Gemcitabine and Afatinib and Gemcitabine combination treatments) after 48
hours (D. SW1990 and E. Capan1). F-G). Isolated SP/CSC population was seeded in
low attachment pates in two groups (Control, Afatinib). IC50 concentration of Afatinib
was added to Afatinib after 24 hours of cell seeding. Effects of afatinib on isolated CSC
populations in tumor sphere assays; tumor sphere counts, and representative
microscopic images are shown (F. SP-SW1990 and G. Capan1).
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Fig.4.5. Afatinib and gemcitabine combination inhibits pancreatic CSCs (PCSCs)
in KPC mouse tumor organoids and primary mouse tumors.
A. Immunofluorescence images of CSC markers and pEGFR in KPC mouse organoids
after

treatment (Control, Afatinib, Gemcitabine and Afatinib with Gemcitabine

combination treatments), scale bars=10 μM, zoomed scale bars=5 μM. B. Quantitative
analysis of CSC marker expression in stained organoids from panel A. C. Immunostained images of CSC markers and pEGFR in mouse primary tumors after treatment
(Control, Afatinib, Gemcitabine, and Afatinib and Gemcitabine combination treatments),
scale bars=10 μM, zoomed scale bars=5 μM. D. Quantitative analysis of CSC marker
expression in stained organoids from panel C.
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Fig.4.6. Afatinib inhibits CSC stemness by downregulating multiple CSC markers
in PC cells.
A. Treatment with afatinib downregulates CSC markers and oncogenic markers in PC
cells. SW1990 cells were seeded for 24 h and subjected to drug treatment in 4 groups
(Control, Afatinib, Gemcitabine and Afatinib, and Gemcitabine combination treatments)
at IC50 concentrations for 48 hours, followed by western blot analysis. B. SP cells
isolated by Hoechst-based FACS express higher amounts of CSC and self-renewal
markers than non-side population (NSP) cells. C. SP-SW1990 cells were treated with
IC20 and IC50 concentrations of afatinib, which downregulates the EGFR family of
proteins and CSC and self-renewal markers. D-E. Immunofluorescence analysis
showing that afatinib represses CSC and self-renewal markers (D. SP-SW1990 and E.
SP-Capan1), scale bars=20 μM. F-G. Quantitative analysis of panels D. and E. (F. SPSW1990 and G. Capan1).
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Fig.4.7. Afatinib decreases the CSC population via EGFR/ERK/FOXA2/SOX9
signaling in PCSCs.
A. PCR array for CSC and self-renewal markers in SP/CSC cells (SP-SW1990) after 4
days of treatment in the culture at IC50 concentrations. B. Afatinib treatment leads to
downregulation of FOXA2 and SOX9 RNA and FOXA2 protein. C. Transient repression
of EGFR by independent siRNAs in SP-SW1990 cells downregulates pERK, FOXA2,
SOX9, DCAMLK1, NANOG, and OCT4. D. Protein expression of pERK, FOXA2, and
SOX9 in SW1990 cells upon treatment with afatinib and gemcitabine alone and in
combination. E. Downregulation of pERK, FOXA2, and SOX9 at IC20 and IC50
concentrations of afatinib in the SP/CSC population of SW1990. F. Downregulation of
SOX9 upon transient knockdown of FOXA2 in the SP/CSC population of SW1990. G.
Immunofluorescence images of afatinib-treated KPC tumor organoids and mouse
primary tumors depicting the reduction of FOXA2 and SOX9. H. Schematic model of the
hypothesized signaling axis by which afatinib inhibits the PCSC, scale bars= 5 μM and 2
μM.
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Supplementary Figures
Supplementary Figure 1.
Effects of afatinib on KC and KPC organoids. A. Microscopic images of H&E-stained PC
organoids from KC mice. B. Microscopic images of KC mouse organoids before and 5
days after treatment, and H&E-stained sections at the end of the treatment. C.
Quantitative analysis of the average size change in control and treated KC PC organoid
groups (Afatinib, Gemcitabine, and Afatinib and Gemcitabine combination treatments)
over 5 days of treatment. D-E. Percentage of organoids estimated to be dead based on
microscopic analysis of the morphology. D. KC tumor organoids. E. KPC tumor
organoids. F. Quantitative analysis of the average size change in control and treated
KPC mouse organoid groups (Afatinib, Gemcitabine and Afatinib and Gemcitabine
combination treatments) at days 4 and 9, indicating desired concentration for treatment
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Supplementary Figure 2.
A). To judge the sensitivity of PC cells (SW1990 and Capan1) to gemcitabine and
afatinib, the IC50s for both drugs were calculated for PC cell lines and their respective
SP/CSC isolated line. B) Mice were orthotopically injected with Capan1 cells and treated
in 4 groups (control, Afatinib, gemcitabine, a combination of gemcitabine and Afatinib)
after 4 weeks of implantation. After 3 weeks of treatment, mice were euthanized, and
internal organs of the mice were harvested, a number of metastatic spots were counted
on each organ. Histogram depicting the number of metastatic spots per organ. C) Dot
plot depicting the correlation between tumor size and metastasis. Metastasis incidence
and primary tumor weights were calculated for the mice and to evaluate the impact of
tumor size on metastasis the correlation between the two was calculated. The figure
depicts a lack of correlation between primary tumor size and metastasis incidence
suggesting the decrease in metastasis could have been due to the therapy and not the
primary tumor size.
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Supplementary Figure 3.
Immunofluorescence images of SW1990 and Capan1 cells, showing downregulation of
self-renewal and oncogenic markers, A. SW1990, B. Capan-1. Scale bars=20μM.

143

144
Supplementary Figure 4.
A. Downregulation of other CSC and self-renewal markers upon treatment (Control,
Afatinib, Gemcitabine, and Afatinib and Gemcitabine combination treatments) in KPC
organoids, Scale bars=10 μM. B. Immunofluorescence images of KPC organoids treated
with afatinib, depicting a reduction in pERK, FOXA2, and SOX9 along with CSC marker
DCAMLK1, scale bars=10 μM. C. Quantitative analysis of CSC and self-renewal
markers of panel B.
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Supplementary Figure 5.
A. FOXA2 binding motifs for SOX9 promoter region. B.Immunofluorescence images of
KPC mouse primary tumors after 4 weeks of afatinib treatment, depicting a reduction in
pERK, FOXA2, and SOX9 along with CSC marker DCAMLK1, scale bars=10 μM. C.
Quantitative analysis of panel B. D. qPCR analysis of CSC and self-renewal markers
found reduced in CSC PCR array from figure 6A.
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CHAPTER 5: SUMMARY, CONCLUSIONS AND FUTURE DIRECTIONS
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5.1 Summary

5.1.1 Organoids for preclinical research
Three-dimensional (3D) cultures use the inherent nature of cells to self-organize
and generate structures that can be programmed to represent an organ or a pathology.
Organoid cultures are the 3D cultivation of source tissue (ranging from cells to tissue
fragments) in a support matrix and specialized media that nearly resembles the
physiological environment. Depending on the source tissue, growth factors, and
inhibitors provided, organoids can be programmed to recapitulate the biology of a
system and progression of pathology. Organoids are genetically and phenotypically
stable, and genetically amenable, making them very suitable tools to study tissue
homeostasis and cancer.
One of the goals of the dissertation was to develop in vitro three-dimensional
models to test therapeutic response. For this, we developed pancreatic cancer
organoids from KC (Kras G12D ; Pdx1Cre), KPC ( Kras G12D ; Trp53R172H/+; Pdx1Cre ) and PDAC
patient samples. This was achieved by modifying protocol from the pioneering Hutch et
al. publication and further standardizing it for our laboratory and experimental needs.
Our organoids grew in culture and demonstrated a change in morphology, from being
organized single cellular ductal structures to unorganized structures. Our tumor
organoids mimic PDAC architecture and environment in vitro, although with a lack of
immune environment. These could be later used as models to study PDAC and drug
response studies. We also report the development of lung organoids and prostate
organoids for future utilization.
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5.1.2 Afatinib targets CSCs in PDAC
PC is a highly lethal disease, and CSCs are major culprits for the aggressive and
metastatic nature of this disease. Present therapies act on differentiated cancer cells
and fail to target CSC. EGFR family of proteins is important for CSC and PC. Afatinib is
an FDA-approved pan-EGFR inhibitor and demonstrated superiority in vitro over
erlotinib, a currently used drug for PC. Here we used traditional monolayer cultures, 3-D
organoid cultures and in vivo animal models to show that inhibition of EGFR family of
proteins using afatinib attenuates PCSC by specifically targeting a novel EGFR/ ERK/
FOXA2/ SOX9 axis and reduces PC growth and metastasis. This study highlights the
importance of targeting CSCs and shows the therapeutic potential of the combination of
afatinib and gemcitabine.
In this study, the primary goal of my dissertation was to develop a targeted
therapy inhibiting cancer stem cells against pancreatic cancer. For which we decided to
focus on targeting EGFR since it is vital for cancer stem cell maintenance and highly
expressed in PC as well as pancreatic cancer stem cells. We have used Afatinib out of
several EGFR family inhibitors. Inhibitory effects of Afatinib were revealed when a
significant reduction in PSCS population was observed after Afatinib treatment.
Additionally, Afatinib inhibited tumorigenic, and self-renewal potential of PCSCs and
down-regulated several vital PCSC markers and self-renewal markers in PC cells as well
as the PCSCs. These results suggested a targeted action of Afatinib on PCSCs, which
are otherwise resistant to most chemotherapeutic drugs including gemcitabine. We
demonstrated in several experiments that gemcitabine treatment, which a very widely
used chemotherapeutic drug against PC, leads to an enrichment of PCSCs when given
alone whereas in combination with Afatinib treatment. This was revealed when after
gemcitabine treatment an increase in PCSC population and enhanced expression of
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CSC markers and self -renewal markers in PC cells but not in combination treatments.
We demonstrated that in an orthotopic mouse model of PC Afatinib treatment inhibited
PC and metastasis, and a combination of Afatinib and gemcitabine showed a better
inhibition when compared to both the drugs alone. We could successfully achieve our
first objective and inhibit PDAC and target PCSCs.

CSCs are known to be major culprits for PDAC metastasis, and hence we
expected that Afatinib treatment alone and in combination would inhibit CSC markers
like CD133, CD44, and SOX9 in orthotopic mouse models tumor sections. Which we
could test and demonstrate by Immunofluorescence staining of these tumor sections.
We also tested the proposed therapy in 3-D tumor organoid model, since they are known
to maintain a robust population of CSCs, and demonstrated a similar reduction in CSC
markers and self-renewal markers. Our PCR Microarray analysis of CSC makers and
self renewal markers revealed a list of 23(ABCB5, ALCAM, BMP7, CD38, CD44,
DACH1, DLL4, FOXA2, ITGA2, JAG1, KLF4, MERTK, NOS2, PECAM1, PLAT, PLAUR,
PTPRC, SNAI1, TAZ, TWIST2, ACTB, B2M and HGDC) makers which were downregulated. Amongst them was FOXA2 which is known to be regulated by and regulate
SOX9 a master regulator for several CSC maintenance genes. FOXA2 is also regulated
by pERK which is a downstream molecule in EGFR signaling. For further investigation, if
this mechanism is being followed, we knocked down EGFR using 2 independent siRNAs
and revealed a downstream downregulation of pERK, FOXA2and SOX 9 along with
other CSC markers. We also knocked down FOXA2 in a similar fashion and observed a
down-regulation of SOX9. We could identify a possible mechanism of action of Afatinib
through EGFR/ERK/FOXA2/SOX9 axis. Immunofluorescent staining of tumor organoids
treated with Afatinib and tumor sections from an orthotopic mouse model of PDAC
showed a similar down-regulation of FOXA2 and SOX9 and hence confirmed or
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mechanism of action in the 3D model and in vivo environments. Overall, we
demonstrated a combination of Afatinib and gemcitabine could provide a potential
targeted therapy for PDAC and its metastasis. My next goal is to understand how
Afatinib and EGFR inhibition modifies the tumor microenvironment in PDAC. We are
currently in the process of investigating the effect of Afatinib on CAFs and developing a
3-D model to provide a more holistic picture of the therapy.

Overall, our studies provide a targeted therapy against PCSCs using Afatinib and
gemcitabine against PDAC and its metastasis. This study will also prove that c ytotoxic
therapies, like Gemcitabine, do not target pancreatic CSC, may be detrimental for
patients. On the other hand, Afatinib, which has a specific action on pancreatic CSC
along with Gemcitabine, would yield much better patient survival.
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5.2 Conclusions
Our overall objective was to generate targeted therapy against pancreatic cancer that
inhibits cancer stem cells as well. We generated organoid cultures to facilitate drug
response studies since 3D organoids provide a more robust platform that simulated
disease architecture, biology and in most part heterogeneity. Since these aspects are
vital to generating translatable therapies and are not recapitulated by traditional culture
methods first part of this thesis holds much significance. We generated organoids from
wildtype murine pancreas, KC, KPC mouse pancreatic cancer models and human
patient samples for immediate use in this study and lung and prostate organoids for
future metastatic studies.
In the second part of my thesis, we evaluate a combination therapy of Afatinib
and gemcitabine against PDAC, its metastasis and cancer stem cell population in PDAC.
We report that Afatinib downregulates stemness properties of pancreatic cancer stem
cells by downregulating EGFR signaling through ERK. The downregulation of
phosphorylated form of ERK decreases FOXA2 expression. Since FOXA2 and SOX9
regulate each other’s expression, a decreased expression of FOXA2 causes a decrease
in SOX9 which results in downregulation of several self-renewal genes and CSC
markers. Due to the inhibitory action of Afatinib an PCSCs it cases a reduction in
metastasis incidence as well as potentiates gemcitabine therapy. Hence, we report a
combination therapy of Afatinib and gemcitabine can inhibit PCSCs and reduce
metastasis as well as inhibit PDAC.
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5.3. Future Directions

5.3.1 Organoids for preclinical research
We successfully generated murine organoids from KC, KPC pancreatic tumors and
wildtype pancreas. We also report the generation of organoids from patient pancreatic
tumors and adjacent normal pancreatic tissue.
Recent findings have reported preservation of histopathological features of the
original tumors both in vivo and following xenotransplantation studies in immunedeficient mice [227]. This suggests that in vitro drug responses can be examined in vivo
in a more complex environment by organoid transplantation. The generated PDAC
organoids can be transplanted in the immune deficient mouse to further validate the
therapy response.
A tumor organoid biobank was generated from 20 CRC patients and their
matching normal tissue [228]. Integration of genomic and monotherapy drug response
data revealed several therapeutically exploitable relations. One of the organoid cultures
from the study was found to be sensitive to inhibition of WNT secretion due to the
presence of RNF43 (WNT antagonist E3 ubiquitin ligase) [147, 229] . Several already
known correlations between genetic mutations and drug responses were also observed
along with differential cytotoxicity profiles with no genetic predictive marker. These
results warrant further validation and hence highlight the need for the development of
more biobanks. Last year a study reported the genetic characterization of organoid
biobank from 39 PDAC patients [184]. The study revealed three distinct PDAC organoid
subtypes based on gene expression subtypes revealing distinct WNT signaling
dependencies. There is a need for the generation of more PDAC organoid biobanks for
the generation of statistically significant inferences about therapy response and
toxicology studies [230].
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Another recent study reported generation of PDAC Organoid lines from 17
patients [176]. Organoids were reported to follow parental tumor histological features
both in vitro and upon xenotransplantation although mutation analysis was not
performed on the organoids. The study reveals incapability of generation of organoid
from poorly differentiated to moderately differentiated PDACs suggesting a modification
of protocol to allow more conclusive therapy response studies. The cell of origin of
PDAC has been a controversial subject. Organoids generated so far have mostly been
of ductal origin, generation of acinar organoids is critical to study the prospective role of
ADM in PDAC (Acinar to ductal metaplasia). A study utilized a genetically engineered
inducible mouse model of ADM to generate organoids that undergo ADM in vitro[231].
The study revealed that both acinar and ductal cells of origin require identical oncogenic
drivers to trigger PDAC but differ in pathophysiology and marker expression. There is a
need for developing protocols to generate acinar cell organoids from patient samples to
allow further studies into studies of PDAC origin.
Patient-derived organoids were generated from metastatic gastrointestinal
cancer in a recent study and used to predict patient therapy response ([232]). Authors
tested a compound library of drugs used either in current clinical trials or clinics. A
positive predictive value of 88% (predicting that a particular drug works) and a negative
predictive value of 100% (predicting that a particular drug does not work) was revealed
in the study suggesting recapitulation of therapy responses from clinical trials. The study
highlights the possibility of the development of personalized medicine platforms[232].
Studies have reported genetic modeling of cancer from normal organoids in CRC
as well as PDAC [176, 233]. Co-culture systems have been established that allow
expansion of hematopoietic cells in vitro with organoids. Short-term maintenance of
intraepithelial lymphocytes has also been achieved in co-culture with intestinal organoids
upon supplementation with interleukin-2 (IL-2), IL-7 and IL-15 (Nozaki et al. 2016).
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Another recent study demonstrated maintenance of CD45+ lymphocytes up to 8 days in
the air-liquid interphase organoid system [234]. These studies highlight the role of
organoid co-culture systems for future studies. We have developed normal lung and
prostrate organoids along with pancreatic cancer organoids. A co-culture system can be
generated that includes normal organoids co-cultures with cancer organoids to simulate
pre-metastatic niche priming and metastasis in PDAC.

5.3.2. Afatinib targets CSCs in PDAC
Our studies have convincingly demonstrated that Afatinib inhibits pancreatic cancer stem
cells via EGFR/ERK/SOX9 axis and in a combination of gemcitabine inhibits pancreatic
cancer and its metastasis.
The interaction between the tumor and its microenvironment is complex, and a
lot is still unknown about the communications between tumor cells and tumor
microenvironment. Hypoxia and immune suppression are major hallmarks of the tumor
microenvironment. The programmed cell death-ligand 1 (PD-L1) on tumor cells is a
major part of the immune suppression module [235]. PD-L1 interacts with programmed
cell death-1 (PD-1) on immune cells in the tumor microenvironment to avoid host
immune surveillance [236]. Tumor cell or normal cell secreted cytokines can enhance
tumor growth, increase metastasis and angiogenesis along with enabling immune
evasion [237, 238]. Several studies have examined inhibition of PD-1/PD-L1 immune
checkpoint signaling to target immune evasiveness of tumors. Expression of PD-L1 has
also been proposed as a predictive marker for checkpoint inhibition therapy [239]. A
correlation has been observed in the expression of PD-L1 in tumors with better
prognosis with EGFR tyrosine kinase inhibitors in NSCLCs ([240]). Better EGFR TKI
treatment outcome has been observed in EGFR mutant NCLCs patients, and EGFR
mutation status is positively associated with high PDL1 expression [241, 242]. Enhanced
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infiltrations by TILs (tumor-infiltrating lymphocytes) is associated with decreased
metastatic recurrence in HER2-positive breast cancer treated with the anti-HER2
monoclonal antibody, trastuzumab [243]. These studies suggest an association between
EGFR/HER2 status and immune evasion and hence, it will be interesting to obs erve the
effects of Afatinib on PDAC immune evasion.
Another study has suggested the role of tumor microenvironment in the
acquisition of resistance to Afatinib treatment in NCLCs through HGF secretion [243].
Several mechanisms have been reported for acquired resistance to Afatinib treatment
although functional studies are needed to prove a causative relationship with resistance
and most of them have been elucidated in lung cancer. Some of these resistance
mechanisms include V843I EGFR mutation and c-MET amplification, enhanced
IL6R/JAK/STAT signaling and expression of FGFR1. Additionally, increased interference
with aerobic glycolysis and autophagy are also proposed to be associated with Afatinib
resistance [228]. A recent study reported acquisition of resistance to EGFR family
inhibitors by activation of STAT3 and simultaneous upregulation of p-c-MET, p-STAT3,
CD44, increased autocrine production of EGFR ligand amphiregulin and differential
activation status of EGFR tyrosine residues as well as downregulation of total and pSRC [190]. The results were majorly cell line based, and further studies are needed to
elucidate the mechanism behind Afatinib resistance.
Afatinib is currently under clinical trials examining its usage as neoadjuvant
therapy. Considering its role against cancer stem cells unlike chemotherapies
administering Afatinib at an early stage may be an effective therapeutic regimen. The
recent release of interim results from phase II ASCENT trial in lung cancer are
encouraging for future studies in this direction. The trial examines Afatinib as the
standard of care treatment with curative intent for EGFR+ stage III NSCLC
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(NCT01553942). Neo-adjuvant afatinib achieved a high objective response rate and
major surgical path responses.
Additionally, the results also suggest that neoadjuvant Afatinib exceeds feasibility over
adjuvant Afatinib in stage III patients. An enhanced progression-free survival has also
been observed although; more data is needed about optimal strategy for stage III
EGFR+ pts [244]. These studies provide a case for testing Afatinib in the neoadjuvant
setting in PDAC along with genotype-based patient stratification.
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